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ABSTRACT 
 
High-grade gliomas are an invasive and deadly brain cancer. We have shown that 
noncanonical NF-κB/RelB signaling can drive invasion in the aggressive mesenchymal 
subtype of glioma. TNF-like weak inducer of apoptosis (TWEAK) can activate 
canonical/RelA and noncanonical/RelB NF-κB signaling, but its role in glioma invasion 
is unclear. Moreover, the relevance of expression of TWEAK and NF-κB-inducing 
Kinase (NIK) in patient gliomas is unknown.  
TWEAK-regulated NF-κB signaling and cell invasion were investigated in both 
established and primary high-grade glioma tumor lines using a three-dimensional (3-D) 
collagen invasion assay. NF-κB proteins regulating both glioma cell invasion and 
expression of Matrix Metalloproteinase 9 (MMP9) in response to TWEAK were 
evaluated using shRNA-mediated loss-of-function. NIK-promoted glioma growth in vivo 
was investigated using an orthotopic xenograft mouse model. Expression of TWEAK, its 
receptor, NIK, and a negative regulator of NIK (altogether termed the TWEAK Axis) in 
glioma tumors was evaluated using microarray data from the NCI-curated TCGA and 
REMBRANDT databases. TWEAK Axis expression was stratified by prognostic factor 
and glioma subtype as well as correlated with expression of both NF-κB genes and 
glioma subtype markers. Patient survival by TWEAK Axis gene expression was 
determined using Kaplan-Meier survival analysis. 
Protein levels of RelB correlate positively with glioma cell invasiveness. Loss of 
RelB attenuates invasion without altering RelA expression or phosphorylation. RelB 
promotes invasion independent of RelA. TWEAK selectively activates noncanonical 
NF-κB signaling through p100-p52 processing and nuclear accumulation of RelB and 
p52. TWEAK, but not TNFα, significantly increases NIK mRNA expression and 
sustains MMP9 mRNA expression. TWEAK-increased invasion is reversible by loss of 
NIK. NIK overexpression increases invasiveness in vitro and gliomagenesis in vivo. 
TWEAK, its receptor, and NIK are expressed primarily in mesenchymal gliomas and 
correlate negatively with survival. 
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Our data establish a key role for NIK and TWEAK in noncanonical NF-κB 
signaling and MMP9-dependent invasion in glioma cells. Meta-analysis of patient 
glioma tumors indicates poorer prognosis with increased TWEAK Axis expression in the 
aggressive mesenchymal subtype. Together, these studies reveal the importance of 
TWEAK and noncanonical NF-κB signaling in glioma cell invasion and rationalize 
therapeutic targeting of TWEAK and NIK in glioma. 
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CHAPTER I  
 
INTRODUCTION AND LITERATURE REVIEW 
 
High-grade gliomas, including Grade III Anaplastic Astrocytoma and Grade IV 
Glioblastoma (GBM), are aggressive tumors of the brain and central nervous system. 
High-grade gliomas are the most common primary brain tumor, with an annual United 
States incidence of 0.37 and 3.19 per 100,000 person-years for anaplastic astrocytomas 
and glioblastomas, respectively [1]. High-grade gliomas can occur de novo or progress 
from low-grade gliomas [2]. First-line therapy includes maximal surgical resection and a 
combination of neoadjuvant as well as post-operative chemotherapy and radiation [3-5]. 
Despite multiple advances in surgical techniques, chemotherapy, and radiotherapy, 
current median survival is 2-7 years for anaplastic astrocytomas and an abysmal 15-
months for glioblastoma [6, 7].  Non-modifiable good prognostic factors include young 
age, female gender, frontal and cortical tumor location, and low tumor grade [8-10]. 
Unlike certain hematological cancers with definitive genetic or chromosomal 
aberrations, high-grade gliomas can be initiated and propagated by diverse networks of 
signaling events [11]. Instead, multiple genetic prognostic factors such as Isocitrate 
Dehydrogenase 1 (IDH1) mutation, O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation status, and 1p/19q chromosomal deletions have been 
identified in high-grade gliomas [12]. These independent genetic factors have shown to 
be clinically relevant in predicting outcome, but the complexity and relation of these 
genetic factors to other genetic and clinical factors is a major area of ongoing research 
[13, 14]. The extent of surgical resection is the foremost treatment prognostic factor [15, 
16], but resection is difficult due to the inherently invasive nature of glioma cells into the 
stroma surrounding the bulk tumor. Chemotherapy and target-specific therapy are 
complicated due to marked heterogeneity of glioma cell populations within the tumor 
[11]. Regardless, tumor relapse is inevitable and poorly amenable to additional resection 
or therapy [17, 18]. Altogether, high-grade gliomas are an incurable and devastating 
 2 
 
disease with considerable challenges to the advancement of basic science and clinical 
outcome. 
 Promising basic science approaches have been developed to understand 
initiation, development, and genetic diversity of high-grade gliomas. Early murine in 
vivo glioma models utilized amplification or ectopic expression of members of the 
Epidermal Growth Factor Receptor (EGFR) pathway to form tumors histologically 
comparable to patient tumors [19]. Although aberrant expression of the EGFR was well-
studied and occurs frequently in glioma, anti-EGFR therapeutic efforts failed and 
highlighted additional genetic complexity mandating a bioinformatical approach [20, 
21]. To that end, the National Cancer Institute (NCI) has founded curated repositories 
such as The Cancer Genome Atlas (TCGA) and Repository of Molecular Brain 
Neoplasia Data (REMBRANDT) to catalog tumor data and the corresponding patient 
data for meta-analysis [22, 23]. Analysis of TCGA data for high-grade gliomas has 
further illuminated increased complexity between glioma samples. Three subtypes were 
described by Phillips et al. in 2008 [11], which were further developed into four distinct 
subtypes proposed by Verhaak et al. in 2010 [24]: Classical, Mesenchymal, Neural, and 
Proneural. A published Gene Set Enrichment Analysis set of the gene signatures for each 
Veerhak subtype is available in Appendix B: Table B1 [24]. The Classical subtype is 
named and characterized by increased expression of EGFR and other Growth Factor 
(GF) family genes. The Mesenchymal subtype is named and characterized by increased 
expression of genes categorically attributed to migratory mesenchymal cells. The Neural 
subtype is named and characterized by increased expression of genes associated with 
terminally-differentiated cells such as neurons and astrocytes. The Proneural subtype is 
named and characterized by increased expression of genes associated with less-
differentiated cells such as neural progenitors and neural stem cells. Theses subtype 
names were designated mostly categorically by gene sets, and considerable efforts are 
being made to understand functional differences between these groups [11, 13, 22, 24]. 
Response to therapy and overall prognosis have been shown to vary between subtypes, 
with the best prognosis in the Proneural subtype and the worst prognosis in the 
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Mesenchymal subtype, though the Mesenchymal subtype is initially amenable to 
conventional therapy [11, 24]. Therefore, therapeutic approaches for glioma must be 
considered in the context of the genetic complexity within and across multiple glioma 
tumors. 
The Mesenchymal subtype is particularly enriched in genes associated with 
cellular invasion, which is a complex cell behavior including interaction with the 
extracellular environment, dynamic cell-shape changes, and cellular locomotion. 
Cellular invasion has been studied as a necessary cell behavior underlying fibroblast 
migration in wound healing [25], neural migration in brain development [26], and 
endothelial invasion in angiogenesis [27, 28].  The initial step in cellular invasion is the 
formation of invadopodia, which are extensions of the cell membrane generated by actin 
polymerization [29]. Invadopodia regularly include coordinated attachment to the 
extracellular matrix, focused proteolysis, and generation of mechanical forces to propel 
the cell [30-32]. Dysregulation of invasion signaling pathways is the defining feature in 
progression of many cancers from carcinoma in situ to invasive carcinoma [33]. 
Protease-dependent invasion is termed “mesenchymal” in light of the necessity of 
mesenchyme-derived cells such as fibroblasts and endothelial cells to infiltrate tissue 
stroma [25, 27]. Protease-independent invasion has been reported in some cell types and 
is termed “amoeboid” [34, 35]. Distinction between the two types is therefore 
determined by activity of matrix-degrading proteolytic enzymes such as Matrix 
Metalloproteinase (MMPs). MMPs are a family of zinc-dependent endopeptidases with 
varying specificities to degrade collagens, laminin, fibronectin, aggrecan, and elastin 
[36]. MMPs can also cleave cell-surface proteins and have been shown to regulate cell 
proliferation, differentiation, and cytokine signaling [37]. MMP9 in particular has been 
shown as an indicator of poor prognosis in many invasive types of cancer, including 
high-grade gliomas [38-42]. Anti-MMP9 antisense RNA has been shown to inhibit 
proliferation of glioma cells in vitro and in vivo, indicating a complex role for MMP9 in 
regulating invasion and proliferation [43]. In addition to aberrant MMP expression, 
upregulation of matrix-adhesion proteins and synthesis of extracellular matrix allow 
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invading cells to preferentially adhere to matrix components and promote invasion [44, 
45]. Pathological deposition of type I collagen and upregulation of collagen-binding 
receptors facilitate the invasive nature of high-grade gliomas [46-48]. Our lab has shown 
that high-grade glioma cells are capable of adhering and invading into 3-dimensional 
collagen matrices [49, 50]. Overall, invasion is a complex cell behavior that requires 
cell-signaling events to coordinate expression and activity of a diverse network of 
cellular events [33]. As such, it is imperative to advance comprehensive understanding 
of the role and capabilities of cell-signaling pathways underlying cellular invasion to 
identify promising targets for therapy. 
Also implicated in Mesenchymal subtype tumors is the increased expression of 
Nuclear Factor kappa-light-chain enhancer of activated B cells (NF-κB) [24], a family of 
transcription factors including RelA, RelB, c-Rel, p105/p50, and p100/p52. NF-κB 
transcription factor dimers recognize a wide variety of DNA 11-mers that make up the 
κB consensus sequence RGGRNNHHYYB  [51] to mediate a wide variety of cellular 
functions including immunity, survival, and cytokine response [52].  Dysregulated NF-
κB signaling has been implicated in a wide variety of cancers, including glioma [53, 54].  
In glioma, NF-κB has been shown to contribute to cell survival, cell differentiation, 
invasion, and radiotherapy resistance [55, 56]. The two major NF-κB pathways are the 
canonical NF-κB pathway and the noncanonical NF-κB pathway (Figure 1).  
Activation of the canonical pathway involves phosphorylation of a hetero-
trimeric Inhibitor of nuclear factor Kappa-B Kinase (IKK) complex (α, β, γ) by cellular 
kinases or cell-surface receptors [57].  IKKβ of the IKK complex phosphorylates 
Inhibitor of Kappa-Beta alpha (IκBα) [58], which sequesters the canonical transcription 
factor heterodimer of RelA and p50 by protein-protein interactions that block the RelA 
& p50 nuclear localization signals (NLS) [59, 60]. Phosphorylation of IκBα allows for 
proteasome-dependent IκBα degradation and translocation of RelA/p50 dimers to the 
nucleus for gene transcription [61]. Dissociation from IκBα and transcriptional activity 
can be altered by phosphorylation of RelA at Serine 536 [62]. Canonical NF-κB 
signaling is terminated by RelA-dependent transcription of IκBα [63, 64].  The  
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Figure 1 Schematic representation of canonical and noncanonical NF-κB pathways. 
 
 
 
noncanonical NF-κB pathway requires constitutively active NF-κB-Inducing Kinase 
(NIK) [65, 66]. NIK protein levels in basal conditions are low due to constant negative 
regulation by TNF Receptor-Associated Factor 3 (TRAF3) resulting in degradation of 
NIK [67].  Extracellular signals can inhibit TRAF3 negative regulation and induce 
accumulation of NIK protein [67, 68]. NIK phosphorylates and forms a complex with 
IKKα that phosphorylates the C-terminus of p100 [69, 70]. p100 sequesters RelB in the 
cytoplasm by protein-protein interactions obscuring the RelB NLS [71].  Phosphorylated 
p100 is partially degraded to p52 by the proteasome, allowing RelB/p52 dimers to 
translocate to the nucleus and activate gene transcription [72, 73]. Noncanonical NF-κB 
signaling is terminated by negative feedback through IKKα-dependent phosphorylation 
and destabilization of NIK [74] as well as NF-κB-dependent transcription of p100 [64]. 
While the canonical NF-κB pathway is ubiquitous in all cells and exists as 
highly-regulated proteins constitutively expressed, the noncanonical NF-κB pathway is 
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differentially expressed and has been shown to control maturation of B cells and 
activation of dendritic cells [75-77].  Knockout of RelA is embryonic lethal [78], 
whereas knockout of noncanonical NF-κB constituents RelB, p100, and NIK result in 
mice with dysregulated B cell maturation and absent peripheral lymph nodes [79-82]. 
Considerable interplay exists within the pathways, including stabilized NIK activating 
the IKK complex [83], RelA-dependent RelB transcription [84], and RelA/p52 and 
RelB/p50 heterodimers [85]. Furthermore, RelB DNA binding activity has been shown 
to be repressed by RelA when both pathways are active [86], further indicating specific 
roles for each pathway. Aberrant canonical NF-κB signaling has been well-studied in 
gliomagenesis. RelA protein overexpression and increased phosphorylation at Serine 
536 has been observed in glioma versus normal brain tissue and correlates positively 
with grade [87]. Increased canonical NF-κB signaling has been shown to promote cell 
survival, invasion, and therapy resistance in glioma [55]. Although noncanonical NF-κB 
has been recently implicated in gliomagensis [24], its role in glioma invasion and 
gliomagenesis is not well-understood. Our lab has shown that expression and activity of 
the noncanonical NF-κB pathway protein RelB promotes glioma cell survival, 
proliferation, and invasion in vitro and in vivo [49]. Additionally, our lab has shown that 
RelB regulates expression of genes associated with the aggressive mesenchymal 
glioblastoma subtype [49] and that activation and overexpression of the noncanonical 
NF-κB pathway increases invasion in vitro and tumor formation in vivo [50]. Therefore, 
further understanding of tumorigenic functions of the noncanonical NF-κB pathway is 
necessary. 
Canonical and noncanonical NF-κB pathways can be activated by extracellular 
cytokines with varying specificity for canonical or noncanonical NF-κB signaling. 
Induction of canonical NF-κB signaling is rapid and transient, while noncanonical NF-
κB signaling has slower onset and longer duration [88]. The most-studied ligands for 
activation of NF-κB pathways are members of the TNF superfamily of ligands and 
receptors. TNF-like Weak Inducer of Apoptosis (TWEAK) is a member of the TNF 
superfamily of ligands encoded by the TNFSF12 gene [89]. TWEAK expression is 
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induced in response to inflammation and has cell-specific effects in promoting 
inflammation, proliferation, and angiogenesis [90-93]. TWEAK is active in either 
membrane-bound or soluble forms [89]. Membrane-bound TWEAK and pathologically 
high concentrations of soluble TWEAK predominately activate the canonical NF-κB 
pathway [94, 95]. At low physiological concentrations, soluble TWEAK is capable of 
activating the noncanonical NF-κB pathway through its receptor Fibroblast Growth 
Factor (FGF)-inducible immediate-early response gene Number 14 (FN14), induction of 
TRAF3 degradation, and accumulation of NIK [94, 96, 97]. TWEAK is expressed in the 
brain [89] and stimulates astrocyte proliferation in concert with EGF signaling [92, 98]. 
TWEAK induces neuronal cell death and increased blood-brain barrier permeability 
through activation of NF-κB [99, 100]. The pro-inflammatory and pro-astrocytic 
functions of TWEAK are an open area of research in neurologic diseases [92, 101, 102]. 
Pro-invasive MMP9 expression and secretion is induced by high-dose TWEAK through 
IκBα degradation, RelA phosphorylation, NIK stabilization, and p100 processing [95].  
TWEAK-stimulated IκBα degradation and RelA translocation has been observed to 
increase migration and synthesis of pro-angiogenic Vascular Endothelial Growth Factor 
in ovarian carcinoma, a highly invasive and metastatic form of cancer [103].   In 
neuroblastoma cells, TWEAK is overexpressed under basal conditions and further 
induced by TNFα [104]. TWEAK stimulates phosphorylation of NF-κB and  activates 
MMP9 [104].TWEAK has been shown to stimulate migration in glioma cells through 
FN14 in a canonical NF-κB-dependent manner and correlate with poor prognosis [105, 
106]. Thus, TWEAK is a relevant inflammatory and pro-tumorigenic cytokine in glioma, 
though its roles in development or progression of glioma are not known.  
The TWEAK receptor FN14, encoded by the TNFRSF12A gene, is a GF-
inducible member of the TNF superfamily of receptors [107]. Prior to its classification 
as the TWEAK receptor, FN14 was an orphan receptor induced by FGF [108, 109]. 
FN14 was shown to increase migration in mesenchymal cells [109] and induce 
proliferation and inhibit terminal differentiation of mesenchymal progenitors in muscle 
repair [110]. Like other members of the TNFR superfamily, the FN14 cytoplasmic tail 
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binds TNF-receptor associated factors (TRAFs) including TRAF1, TRAF2, TRAF3, and 
TRAF5 [107, 111]. Similar to other receptors that activate noncanonical NF-κB 
signaling, engagement of FN14 with its ligand TWEAK recruits TRAF3 for degradation 
and results in stabilization of NIK [96, 97]. Activation of FN14 has been shown to result 
in transcription and secretion of MMP9 in glioma, neuroblastoma, and prostate cancers 
[95, 104, 112]. FN14 overexpression has been identified in invasive cancers of the liver, 
lung, breast, and prostate in addition to CNS malignancies such as neuroblastoma, and 
glioma [103-105, 108, 112-114]. FN14 expression is induced by activation of the Human 
EGF Receptors (HERs) in HER2 and HER3-positive breast cancers [113]. RNA 
silencing of FN14 decreases MMP9 mRNA expression and migration of HER-positive 
breast cancer cells [113]. Overexpression of human FN14 in non-small cell lung 
carcinoma cells increases cell migration as well as the frequency of metastases in mouse 
xenografts [114]. FN14 is highly expressed in hepatocytes during liver regeneration as 
well as in hepatocellular carcinoma  (HCC) cells [108, 115]. Blockade of FN14-
TWEAK signaling using a decoy FN14 fusion protein induces HCC cell procaspases and 
apoptosis in vitro as well as reduces HCC xenografts in vivo [115].  RNA silencing of 
TWEAK and FN14 decrease NF-kB phosphorylation and viability of neuroblastoma 
cells [104]. In glioma cells, overexpression of FN14 and its activate by TWEAK has 
been shown to promote glioma cell motility and survival through activation of IKKβ and 
the canonical NF-κB pathway [105, 116]. Initial reports indicated that FN14 is expressed 
at low levels in the brain [109], while more recent research has shown that FN14 is 
overexpressed in glioma and correlates with poor prognosis [105, 108]. The functional 
importance of FN14 signaling in the transformation and progression of glioma is not 
understood. 
NIK was originally described as an activator of the canonical NF-κB pathway 
[117], but was discovered as essential for transmitting extracellular signals from cell-
membrane receptors for all ligands known to activate the noncanonical NF-κB pathway 
[74, 81, 118], including TWEAK [97]. NIK is a Mitogen-Activated Protein Kinase 
Kinase Kinase (MAP3K) and its designated gene symbol is MAP3K14. A loss-of-
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function mutation in NIK results in a B-cell-mediated alymphoplasia and 
immunodeficiency [82]. Conversely, elevated NIK activity has been recently implicated 
in hematological and ovarian cancers [119-122]. Loss of TRAF3 negative regulation of 
NIK can induce proliferation and malignancy of B cells [123]. NIK was identified in a 
differential gene expression study to promote resistance to ionized radiation when 
treated with a radioprotective compound [124]. shRNA-mediated knockdown of NIK 
abrogated the elongation, migration, and invasion of glioblastoma cells treated with a 
Second Mitochondrial Activator of Caspases (SMAC) mimetic [125]. Although 
understandings of NIK structure, regulation, and contribution to hematological 
malignancies have improved considerably in the last decade, tumorigenic functions of 
NIK in progression or maintenance of glioma are poorly understood. 
Recent studies discussed here have advanced the fundamental understanding of 
glioma progression, NF-κB signaling, and TWEAK/FN14 signaling. The interrelation of 
these observations is still unclear and merits investigation. A combination of reports 
demonstrate NF-κB genes implicated in the aggressive Mesenchymal glioblastoma 
subtype [24], a pro-invasive function of noncanonical NF-κB transcription factor RelB 
[49], and TWEAK/FN14 overexpression inducing glioma invasion and correlating with 
poor outcome [105, 106]. Altogether, this implicates TWEAK/FN14 extracellular 
activation of NIK by preventing TRAF3 negative regulation as a glioma-relevant 
signaling axis yet to be specifically evaluated in glioma invasion. We designate 
TWEAK, FN14, NIK, and TRAF3 as the TWEAK Axis. In this work, we investigate 
how TWEAK promotes invasion through noncanonical NF-κB signaling and the 
significance of gene expression of the TWEAK Axis in clinical gliomas. Our specific 
questions for this dissertation are: 
 How does upstream and extracellular activation of the noncanonical NF-κB 
pathway affect glioma invasion and tumorigenesis? 
 What is the clinical context for expression of TWEAK-Axis genes? 
In this thesis, we demonstrate a role for TWEAK and NIK in RelB-dependent 
noncanonical NF-κB signaling and high-grade glioma invasion. We utilized an in vitro 
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collagen I invasion model for understanding functional significance of cell-signaling 
events through the TWEAK Axis and noncanonical NF-κB pathway. We used an in vivo 
mouse orthotopic xenograft model to demonstrate that overexpressing NIK is pro-
tumorigenic in glioma. Furthermore, we investigated gene expression and clinical data 
from NCI-curated databases for clinical correlations of the TWEAK Axis in glioma 
pathogenesis and patient outcome. Our results indicate that TWEAK, FN14, and NIK 
have a relevant biological and clinical role in high-grade gliomas, particularly the 
Mesenchymal subtype. These findings support previous reports and advance the field of 
TWEAK-FN14-noncanonical NF-κB signaling in high-grade gliomas. 
  
 11 
 
CHAPTER II  
 
TWEAK PROMOTES GLIOMA CELL INVASION THROUGH INDUCTION OF 
NIK AND NONCANONICAL NF-κB SIGNALING*
 
Background 
The aggressive, infiltrative growth of gliomas renders them highly refractory to surgery, 
radiation and chemotherapy. Thus, understanding the biochemical and molecular 
pathways that control glioma cell invasion is critical for identifying more effective 
therapeutic targets. Aberrant activation of the canonical NF-κB pathway is well-
documented in a variety of malignancies [126, 127] and plays important roles in 
regulating glioma invasion and tumor progression [55, 56, 128]. However, specific roles 
for the noncanonical NF-κB pathway in tumor pathogenesis, particularly in solid tumors 
of the central nervous system (CNS), are poorly understood. 
NF-κB proteins are evolutionarily-conserved transcription factors that play 
central roles as coordinators of key biological processes including immunity, 
inflammation, cell death and survival. The five mammalian family members RelA (p65), 
RelB, c-Rel, NFKB1 (p105/p50), and NFKB2 (p100/p52) share an evolutionarily-
conserved Rel homology domain that mediates DNA binding and dimerization with 
other NF-κB subunits. NF-κB complexes are held in the cytoplasm in an inactive state, 
bound to members of the NF-κB inhibitor (IκB) family, which includes IκBα. In 
response to specific extracellular signals such as the cytokine tumor necrosis factor-α 
(TNFα), activation of canonical NF-κB signaling is triggered by signal-induced 
phosphorylation and degradation of IκBα, followed by nuclear translocation of the 
active, liberated RelA-p50 complexes. IκBa phosphorylation-induced degradation and 
                                                 
*Reprinted with permission from “Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) 
promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-
κB signaling” by EM Cherry, DW Lee, JU Jung, R Sitcheran 2015. Molecular Cancer, Volume 14, Pages 
1-13, Copyright [2015] by BioMed Central. 
 12 
 
activation of the canonical NF-κB pathway is dependent on IκB kinase-β (IKKβ). 
Noncanonical NF-κB signaling is mediated by RelB-p52 heterodimers whose 
activation is dependent on NF-κB-inducing kinase (NIK). NIK, a Mitogen-Activated 
Protein Kinase Kinase Kinase (MAP3K14), is regulated primarily through protein 
stabilization [129]. In unstimulated cells, NIK interacts with TNF Receptor-Associated 
Factor 3 (TRAF3) in a multi-subunit E3 ubiquitin ligase complex which leads to NIK 
polyubiquitination and proteasomal degradation [130]. Consequently, NIK protein levels 
are maintained at low levels. A critical step in activation of noncanonical NF-κB 
signaling is the ubiquitination-mediated proteasomal degradation of TRAF3, which 
stabilizes NIK protein, leading to IKKα activation and phosphorylation of p100, an 
inhibitory IκB-like protein that retains RelB in the cytoplasm. Phosphorylation of p100 
leads to its proteolytic processing to form p52, culminating in nuclear translocation of 
transcriptionally active RelB-p52 heterodimers [66, 120]. Notably, unlike other NF-κB 
proteins, RelB is inherently unstable and its protein levels are stabilized by interaction 
with p100/p52 in the cytoplasm [131] and DNA binding in the nucleus [132]. 
The noncanonical NF-κB pathway can be specifically activated by signals such 
as B-cell-activating factor receptor (BAFFR) [129]. However, some signals, such as 
TNF-like weak inducer of apoptosis (TWEAK) have been shown to regulate both the 
canonical and noncanonical NF-κB pathways for sustained NF-κB activation [97]. 
TWEAK and its receptor, Fibroblast Growth Factor (FGF)-inducible immediate-early 
response gene Number 14  (FN14), have recently been implicated in tumor cell 
pathogenesis [104, 133] and upregulation of MMP9 [95], which is generally associated 
with poor disease prognosis due to its ability to promote tumor growth, migration, 
invasion, and metastasis [39]. However, the functional outcomes of TWEAK signaling 
in glioma with regard to specific downstream NF-κB signaling events are not clear. We 
have previously demonstrated that the noncanonical NF-κB protein, RelB, is highly 
expressed in a subset of aggressive, mesenchymal glioma, where it is a potent driver of 
oncogenesis and a predictor of survival in human patients [49]. In this study, we 
investigate the effects of TWEAK on noncanonical NF-κB/RelB signaling, MMP9 
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expression, and glioma invasion. 
 
Results 
The invasive potential of glioma tumor lines positively correlates with RelB expression 
Because aggressive invasion of high-grade gliomas into normal health tissue is a 
significant barrier to treatment, we sought to further evaluate the relationship between 
NF-κB signaling pathways and glioma cell invasion. First, we analyzed the invasive 
potential of both established high-grade glioma tumor lines (U87 & U373) and primary 
brain tumor-derived lines (BT25, BT114, BT116, BT132) using a three-dimensional (3-
D) collagen matrix assay [28]. Compared with two-dimensional (2-D) assays, modeling 
tumor cell invasion in 3-D collagen matrices better reflects both the in vivo cell-cell and 
cell-extracellular matrix interactions within a tumor [134], as well as the significantly 
elevated levels of collagen in the adult brain tumor microenvironment [47]. Analysis of 
side-view images of cells invading the collagen matrix and quantification of invading 
cells demonstrated that BT25, BT116, and U87 cells were the most invasive tumor lines, 
while BT132, BT114 and U373 were significantly less invasive (Figure 2A). 
Quantification of invasion density confirmed these observations (Figure 2B).  
Next, we analyzed expression of canonical and noncanonical NF-κB proteins in 
the different glioma tumor lines. Western blot analysis demonstrated that, compared with 
BT25 and BT114 cells, BT116, BT132, U87 and U373 cells exhibited higher levels of 
phosphorylated RelA at serine 536 (RelA-P536), a marker of enhanced NF-κB 
transcriptional activation potential [135, 136], while total RelA levels were comparable 
in all cell lines (Figure 2C). We noted that neither total RelA, nor RelA-P536 levels 
correlated with invasiveness. For example, low RelA-P536 is seen in both invasive 
BT25 cells,as well as low-invasive BT114 cells. Likewise, high RelA-P536 expression 
was observed in both high-invasive BT116 and low-invasive BT132 (see Figure 2A, B). 
In contrast to RelA, RelB protein levels were more varied in the different glioma lines, 
and high RelB-expressing cells (U87, BT25, and BT116) invaded much more efficiently 
than low RelB-expressing cells (BT132, BT114 and U373). These results demonstrate  
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Figure 2 Glioma cells have diverse invasion phenotypes that correlate positively with RelB 
expression. Equal numbers of glioma cells from indicated cell lines were seeded on 3-D collagen matrices 
and allowed to invade for 48 h, fixed with 3% glutaraldehyde, and stained with 0.1% toluidine blue. (A) 
Side-view light microscopy images were taken from thin slices of the collagen matrices at 10x 
magnification. White arrowheads indicate cell monolayer. Scale bars = 100 μm. (B) Quantification of 
invasion density for cell lines in Figure 2A. Data represent average numbers of invading cells per 1-mm2 
field (n = 3 wells) ± SEM. (C) Western blot of whole-cell lysates from glioma lines using the indicated 
antibodies. 
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that levels of RelB, but not RelA or RelA-P536, strongly correlate with the invasive 
potential of glioma cells. 
 
RelB poteniates glioma invasion independently of RelA 
We have previously reported that loss of RelB in glioma significantly reduces the 
number and depth of invading tumor cells [49]. To further characterize and compare the 
roles of RelA and RelB in invasion, we used lentivirally-delivered shRNA to inhibit 
expression of these proteins in the highly invasive BT25 and U87 cells (Figure 3A). 
Side-view images of 3-D collagen invasion matrices and quantification of invading cells 
demonstrated that loss of either RelA or RelB each resulted in a significant decrease of 
glioma invasive potential (Figure 3B, C and Appendix A: Figure A1A, B). In shRelA 
cells, a significant loss of RelB was observed (Figure 3A), consistent with the known 
ability of RelA to regulate expression of RelB [84]. In contrast, RelA protein levels were 
not significantly affected by loss of RelB (Figure 3A), demonstrating that the loss of 
invasive potential of in shRelB cells was mediated by RelB and was not due to loss of 
signaling through the canonical RelA-dependent NF-κB pathway. 
Next, we tested whether ectopic expression of RelB could restore the invasive 
potential of RelA knockdown cells. U87 shRelA cells were transduced with lentivirus to 
express either a control vector or RelB. We observed that ectopic expression of RelB in 
the RelA knockdown cells was approximately 5-fold higher than endogenous RelB 
expression in shControl cells (Figure 3D and Appendix A: Figure A1C). Notably, 
overexpression of RelB did not affect shRNA-mediated knockdown of RelA and also 
did not alter the levels of either total or phosphorylated RelA (Figure 3D). RelB was 
nevertheless able to restore the loss of invasion observed in RelA knockdown cells 
(Figure 3E). These results demonstrate that in glioma cells with attenuated levels of 
RelA protein, RelB can rescue invasion without increasing the expression or activity of 
RelA and canonical NF-κB signaling. 
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Figure 3 RelB potentiates glioma invasion independently of RelA. (A) Western blot of whole-cell 
lysates from NSC-cultured BT25 and U87 cells transduced with lentiviral vectors expressing shRNA 
targeting RelA (shRelA), RelB (shRelB), or a scrambled control (shCon). (B) Representative images of 
invading shRNA-transduced glioma cells at 48 h. White arrowheads indicate monolayer. Scale bars = 100 
μm. (C) Quantification of invasion density at 48 h for BT25 and U87 knockdown cell lines. Data represent 
average numbers of invading cells per 1-mm2 field (n = 3 wells) ± SEM. ***p < 0.001 relative to shCon 
using One-way ANOVA with Tukey’s HSD. post-test. (D) Western blot of whole-cell lysates from U87 
shRelA cells transduced with lentiviral vectors containing RFP cDNA (+Vector) or RelB cDNA (+RelB). 
(E) Quantification of invasion density at 48 h for U87 shRelA cells in Figure 3D. ***p < 0.001 relative to 
shCon using One-way ANOVA with Tukey’s HSD post-test. †Data contributed by DW Lee. 
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Figure 3. RelB potentiates glioma invasion independently of RelA. 
† 
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TWEAK promotes glioma cell invasion and predominantly activates noncanonical 
NF-κB signaling 
TWEAK has been reported to be an activator of both canonical and noncanonical NF-κB 
pathways [97, 137, 138]. However, very high concentrations of TWEAK (100 ng/ml) are  
required for activation of RelA [95, 137]. We observed that treatment with a low, 
physiological concentration of TWEAK (10 ng/ml) was sufficient to increase glioma 
invasion in the 3-D collagen matrices (Figure 4A). Thus, we next examined the effect of 
TWEAK on NF-κB signaling. Glioma cells were treated with TWEAK (10 ng/ml) and 
western blot analysis was performed with cytoplasmic and nuclear protein lysates. We 
observed that TWEAK robustly induced noncanonical NF-κB activity, as evidenced by 
increased p100 processing to p52, as well as nuclear accumulation of both RelB and p52  
 (Figure 4B). Increased nuclear accumulation of RelB was observed as early as 15 
minutes after treatment with TWEAK and reached peak levels at 4 hours, with a 
concurrent increase in p100 processing and nuclear p52 and sustained levels of both 
proteins after 48 hours (Figure 4B). Notably, nuclear translocation of RelA, RelA-P536,  
p105, p50, or c-Rel was not induced by TWEAK stimulation (Figure 4B and Appendix 
A: Figure A2A). Moreover, no degradation of IκBα was observed in response to 
TWEAK (Figure 4B). In contrast, treatment with TNFα, a potent inducer of canonical 
NF-κB activity, led to rapid degradation of IκBα, and phosphorylation and nuclear 
translocation of RelA (Figure 4C), demonstrating that these cells have fully-functional 
canonical NF-κB signaling. TNFα also induced RelB nuclear accumulation and p100 
processing, albeit more transiently compared with TWEAK treatment (Figure 4C). As 
with TWEAK, TNFα induced RelB nuclear localization starting at 15 minutes, reaching 
maximal levels at 4 hours. However, levels of nuclear RelB returned to basal by 24–48 
hours (Figure 4C). Similar results were observed in TNFα- and TWEAK-treated BT25 
and U87 cells (data not shown). Finally, consistent with predominant activation of the 
noncanonical NF-κB pathway by TWEAK, we observed a robust increase in NIK 
mRNA levels as early as one hour after TWEAK treatment (Figure 4D). TNFα, on the 
other hand, did not significantly alter NIK expression (Figure 4D). Induction of elevated  
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Figure 4 TWEAK induces invasion, NIK mRNA expression, and noncanonical NF-κB nuclear 
translocation. (A) Quantification of BT116 invasion density at 48 h with or without 10 ng/ml TWEAK in 
the collagen matrix. Data represent average numbers of invading cells per 1-mm2 field (n = 3 wells) ± 
SEM. *p < 0.05 relative to vehicle control using unpaired Student’s t-test. (B) Western blot analysis of 
proteins from cytoplasmic and nuclear fractions of BT116 cells stimulated with 10 ng/ml TWEAK for the 
indicated times using the indicated antibodies. (C) Western blot analysis of cytoplasmic and nuclear 
fractions as in Figure 4B post-stimulation with 10 ng/ml TNFα for the indicated times. (D) qRT-PCR 
analysis of NIK mRNA expression from BT116 cells. mRNA was collected at indicated time points after 
stimulation with TWEAK (10 ng/ml) or TNFα (10 ng/ml). Data represent average mRNA expression 
relative to RPLP0 mRNA (n = 3 replicates) ± SD. †Data contributed by DW Lee. 
† 
† 
† 
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NIK mRNA synthesis at 4 hours post-TWEAK also correlated with increased protein 
levels (Appendix A: Figure A2B). Together, these data provide strong evidence 
supporting the ability of TWEAK to predominantly promote activation of the 
noncanonical NF-κB pathway in glioma. 
 
TWEAK-dependent regulation of MMP9 expression is mediated by the noncanonical 
NF-κB pathway 
Matrix Metalloproteinases (MMPs) play key roles in many aspects of cancer 
pathogenesis, including regulation of extracellular matrix remodeling during invasion 
[39]. To investigate the role of MMPs in glioma cells invasion, we tested the effects of a 
pan MMP inhibitor, GM6001, in our 3-D invasion assays. We observed that GM6001 
blocked invasiveness of untreated cells in a dose-dependent manner, with almost 
complete inhibition of invasion with 1µM (Figure 5A, Appendix A: Figure A3A). The 
ability of TWEAK to promote invasion was also proportionately reduced with GM6001 
treatment (Figure 5A). To examine the effect of TWEAK on expression of MMPs, we 
performed qRT-PCR on BT116 glioma cells treated with TWEAK (10 ng/ml) for 24 
hours. Results from these experiments demonstrate that TWEAK robustly induced 
expression of MMP9 and negligibly affected expression of MMP2 and MMP14 (Figure 
5B). Increased MMP9 expression was first discernable at 4 hours and peaking at 24–48 
hours after TWEAK stimulation, concurrent with induction of RelB and p52 nuclear 
localization (see Figure 4C). TNFα also increased expression of MMP9 with more rapid 
kinetics but overall lower levels of induction compared to TWEAK (Figure 5B). 
Given these findings, we surmised that the lower efficacy of GM6001 towards 
MMP9 activity (see Methods) might account for its inability to attenuate TWEAK-
induced invasion. Therefore, to test the role of MMP9 in TWEAK-induced invasion we  
performed the 3-D invasion assay in the presence of a selective MMP9 inhibitor. 
MMP9Inhibitor I did not have a significant effect on untreated U87 cells, however, the 
ability of TWEAK to promote invasion was significantly attenuated (Appendix A: 
Figure A3B). Similar results were observed with BT116 cells (data not shown). 
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Figure 5 MMPs are required for glioma invasion and TWEAK-induced MMP9 expression is p52-
dependent. (A) Quantification of invasion density at 48 h for BT116 cells with or without 10 ng/ml 
TWEAK in the collagen matrix. Cells were treated during the 48 h invasion assay with broad-spectrum 
MMP inhibitor GM6001 at indicated concentrations. Data represent average numbers of invading cells per 
1-mm2 field (n = 3 wells) ± SEM. **p < 0.01 ***p < 0.001 between indicated groups using unpaired 
Student’s t-test. (B) qRT-PCR analysis of MMP mRNA expression in cultured BT116 cells. mRNA was 
collected at indicated time points after stimulation with TWEAK (10 ng/ml) or TNFα (10 ng/ml). Data 
represent average mRNA expression relative to GAPDH mRNA and normalized to untreated cells at t = 0 
(n = 3 replicates) ± SD. (C) Western blot of whole-cell lysates from cultured BT25, BT116, and U87 cells 
transduced with shRNA targeting p100/p52 (NFKB2) or a scrambled control (Control). Lysates were 
collected at 48 h after stimulation with 10 ng/ml TWEAK or vehicle control. White arrowhead indicates 
p52 band. Black arrowhead indicates non-specific band. (D) qRT-PCR analysis of MMP9 mRNA 
expression from cell lines in Figure 5C. mRNA was collected at 48 h after stimulation with 10 ng/ml 
TWEAK or vehicle control. Data represent average MMP9 mRNA expression relative to RPLP0 mRNA 
and normalized to untreated control (n = 3 replicates) ± SD. ***p < 0.001 between indicated groups 
determined by unpaired Student’s t-test for each cell line. †Data contributed by DW Lee. 
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Figure 5 MMPs are required for glioma invasion and TWEAK-induced MMP9 expression is p52-
dependent. 
 
† 
† 
† 
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To determine whether noncanonical NF-κB activity is required for TWEAK-
induced MMP9 expression, we transduced BT25, BT116, and U87 cells with shRNAs 
targeting NFKB2 (p100) or a scrambled shRNA. Western blot analysis demonstrated 
that loss of NFKB2 resulted in a decrease in p100 protein levels and TWEAK-dependent 
processing to p52 (Figure 5C). TWEAK induction of RelB protein was also attenuated in 
NFKB2 knockdown cells (Figure 5C). qRT-PCR analyses demonstrated that although 
basal MMP9 mRNA levels were comparable between shNFKB2 and shControl lines, the 
ability of TWEAK to induce MMP9 expression was significantly impaired in NFKB2 
knockdown cells (Figure 5D). These results demonstrate that TWEAK-mediated 
induction of NIK and noncanonical NF-κB pathway are critical for increasing expression 
of MMP9 and glioma cell invasion. 
 
Expression of NIK promotes gliomagenesis in vivo 
Our data thus far demonstrate that a low concentration of TWEAK promotes invasion 
and predominantly activates noncanonical NF-κB signaling in glioma tumor lines with 
high RelB expression. Notably, we observed that similar to BT116 cells, TWEAK was 
also able to promote invasion in BT114 glioma cells, which are minimally invasive and 
express low levels of RelB (Figure 6A; also see Figure 2). TWEAK also significantly 
increased levels of NIK mRNA in these cells (Figure 6B). Therefore, we investigated  
whether NIK could potentiate noncanonical NF-κB signaling and enhance gliomagenesis 
in vivo using an orthotopic mouse xenograft model. Ectopic expression of NIK in BT114 
cells increased p100 processing to p52 compared with BT114 cells expressing vector 
control, indicating that the ectopically expressed NIK was functional (Figure 6C). RelA-
P536, IκBα, p50, and c-Rel levels were unaffected by NIK overexpression, indicating 
that NIK did not significantly affect the canonical NF-κB pathway (Appendix A:  
Figure A4A). BT114-control and BT114-NIK cells were fluorescently labeled and 
injected into the right cortex of CD-1 nude mice. 3-D tomographic reconstruction of 
fluorescent images taken in vivo revealed that BT114-NIK cells formed larger and more-
dispersed tumors compared with BT114-control cells (Figure 6D). Quantification of   
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Figure 6 NIK mRNA is up-regulated by TWEAK and NIK protein overexpression promotes 
tumorigenesis. (A) Quantification of BT114 invasion density at 48 h with or without 10 ng/ml TWEAK 
in the collagen matrix. Data represent average numbers of invading cells per 1-mm2 field (n = 3 wells) ± 
SEM. ***p < 0.001 relative to vehicle control using unpaired Student’s t-test. (B) qRT-PCR analysis of 
NIK mRNA expression from BT114 cells. mRNA was collected at 48 h after stimulation with 10 ng/ml 
TWEAK or vehicle control. Data represent average NIK mRNA expression relative to RPLP0 mRNA and 
normalized to untreated control (n = 3 replicates) ± SD. ***p < 0.001 relative to vehicle control using 
unpaired Student’s t-test. (C) Western blot analysis of BT114 glioma cells transduced with lentivirus 
containing NIK cDNA or luciferase cDNA (Con) using the indicated antibodies. (D) Representative IVIS 
images of 3-D rendering of tumors derived from DiD-stained intracranial-injected BT114-control (n = 7 
mice) or BT114-NIK (n = 9 mice) cells at 14 and 24 days post-injection (n = 3 mice per group). Numbers 
indicate scale of Signal Intensity for each image. (E) Quantification of BT114 brain tumors in Figure 6D 
at 30 days. Data represent average tumor volume ± SEM. *p < 0.05 relative to BT114 control using 
unpaired Student’s t-test. (F) Representative IVIS ex-vivo images of DiD-stained BT114 brain tumors in 
Figure 6D at 58 days post-injection. †Data contributed by DW Lee, ‡ Data contributed by J Jung. 
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Figure 6 NIK mRNA is up-regulated by TWEAK and NIK protein overexpression promotes 
tumorigenesis. 
 
‡ ‡ 
‡ 
† † 
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tumor volume demonstrated that BT114-NIK cells formed significantly larger tumors 
(Figure 6E). Finally, ex vivo images taken 58 days after intracranial injection confirmed 
that BT114-NIK cells formed significantly larger tumors compared with BT114-control 
(Figure 6E,F). Taken together, these data reveal a key role for NIK and noncanonical 
NF-κB signaling in glioma pathogenesis. 
 
NIK promotes invasion and mediates TWEAK-induced invasion in vitro 
Constitutive activity of endogenous NIK is negatively regulated by polyubiqutinylation 
and proteasome-mediated degradation. TRAF3 is the most well-studied recruiter of a 
TRAF2/cIAP2/cIAP3 E3 ligase complex, but inhibition of this process is complex due to 
multiple ubiquitinylation sites and a large TRAF3-binding domain in the NIK protein. 
Multiple point mutations or a large domain deletion in the NIK protein could introduce 
considerable variability in the stability and activity of the NIK protein. We sought to 
artificially increase NIK activity by creating a mutant NIK construct with an alanine 
substitution at serine 867 (NIK-S867A) identified as the site for phosphorylation by 
TANK-Binding Kinase 1 (TBK1) in an alternate degradation pathway [139]. 
Transduction of BT114 and U87 cells with wild-type NIK (BT114-NIK and U87-NIK) 
and mutant NIK (BT114-NIK S867A and U87-NIK S867A) resulted in comparable 
levels of NIK protein under basal conditions (Figure 7A). Increased p100 processing to 
p52 was observed in BT114-NIK, U87-NIK, and U87-NIK S867A cells compared to 
control-transduced cells. BT114-NIK S867A did not significantly increase p52 
production versus detectable p52 levels seen in unstimulated BT114 control-transduced 
cells (see Figure 6C). Side-view images of cells invading the collagen matrix 
demonstrated that BT114-NIK and U87-NIK cells were slightly more invasive than 
BT114-control and U87-control, while BT114-NIK S867A and U87-NIK S867A cells 
were significantly more invasive than BT114-control and U87-control lines (Figure 7B). 
Quantification of invasion density confirmed these observations (Figure 7C). 
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NIK acts as the receptor-activated MAP3K for all known ligands that specifically 
activate noncanonical NF-κB signaling [81, 118, 123]. We performed a NIK loss-of-
function study to determine whether NIK acts as an intermediary in the observed  
TWEAK-induced induction of noncanonical NF-κB signaling and TWEAK-stimulated 
invasion. BT114 cells were transduced with shRNA targeting NIK (shNIK) or a 
scrambled shRNA control (shCon). Detection of endogenous NIK expression in 
transduced BT114 lines required treatment with proteasome inhibitor MG132 and could 
be increased with TWEAK treatment (Figure 7D). Functionality of the shNIK construct 
was verified by undetectable NIK protein in BT114-shNIK cells even with both MG132 
and TWEAK treatment. TWEAK treatment induced p100 processing in BT114 lines, 
consistent with previous induction in other lines (see Figure 5C). Some p52 production 
was observed in TWEAK-stimulated BT114-shNIK cells, indicating incomplete 
knockdown and consistent with constitutive activity. As expected, MG132 treatment 
inhibited p100 processing to p52. TWEAK significantly increased invasion in BT114-
control cells, consistent with the response seen in wild-type BT114 cells (Figure 7E, see 
Figure 6A). The significant increase in invasion with TWEAK treatment was lost in the 
BT114-shNIK line (Figure 7E). A slight increase in invasion in the BT114-shNIK cells 
is consistent with detectable NIK activity from incomplete knockdown (see Figure 7D). 
Together these results indicate that increased NIK activity is sufficient to increase 
glioma invasion and that NIK is a significant intermediary in TWEAK-induced invasion. 
 
Discussion 
Aberrant activation of the canonical NF-κB pathway has been correlated with the 
promotion of brain cancer cell survival and invasion. However, roles for the 
noncanonical NF-κB pathway in CNS pathologies are less clear. RelB expression was 
previously described to be elevated in the aggressive mesenchymal glioma subtype [24] 
and we have recently identified a functional role for RelB as a key driver of 
mesenchymal gene expression and tumorigenesis [49]. A critical feature of the 
noncanonical NF-κB signaling pathway is its dependence on the regulation of NIK  
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Figure 7 NIK overexpression increases invasion and NIK knockdown inhibits TWEAK-induced 
invasion. (A) Western blot analysis of whole-cell lysates from BT114 and U87 glioma cells transduced 
with lentiviral vectors containing NIK cDNA, NIK S867A cDNA, or luciferase cDNA (Con) using the 
indicated antibodies. (B) Representative images of invading NIK-transduced glioma cells at 48 h. White 
arrowheads indicate monolayer. Scale bars = 100 µm. (C) Quantification of invasion density at 48 h for 
BT114 and U87 ectopic NIK expression cell lines. Data represent average numbers of invading cells per 
1-mm2 field (n = 3 wells) ± SEM. **p<0.01 ***p < 0.001 relative to Con using One-way ANOVA with 
Tukey’s HSD. post-test.  (D) Western blot of whole-cell lysates from cultured BT114 cells transduced 
with shRNA targeting NIK (shNIK) or a scrambled control (shCon). Cells were pre-treated for 1 h with 5 
µM proteasome inhibitor MG132 or vehicle control prior to stimulation with or without 10 ng/ml TWEAK 
for 6 h as indicated. (E) Quantification of invasion density in BT114 knockdown cell lines at 48h with or 
without 10 ng/ml TWEAK in the collagen matrix. Data represent average numbers of invading cells per 1-
mm2 field (n = 3 wells) ± SEM. ***p < 0.001 relative to vehicle control using unpaired Student’s t-test. 
†Data contributed by DW Lee 
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Figure 7 NIK overexpression increases invasion and NIK knockdown inhibits TWEAK-induced 
invasion. 
† 
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protein stability through proteasome-dependent degradation [130]. We show that a low 
concentration of TWEAK (10 ng/ml) preferentially and potently activates the 
noncanonical NF-κB signaling cascade as evidenced by induction of p100 processing to 
p52 and nuclear accumulation of p52 and RelB (see Figure 4B). At this concentration, 
TWEAK failed to induce significant IκBα degradation and nuclear translocation of RelA 
(see Figure 4B), suggesting minimal TWEAK-induced activation of the canonical NF-
κB pathway in glioma cells. Moreover, since a low concentration of TWEAK is 
sufficient to promote noncanonical NF-κB-mediated cell invasion, this pathway may be 
extremely important for initiating early, aggressive tumor dissemination. 
Interestingly, we observed that TWEAK can promote noncanonical NF-κB 
signaling at the pre-translational level, as evidenced by accumulation of NIK mRNA in 
response to treatment with TWEAK. This induction of NIK mRNA was specific for 
TWEAK since TNFα, a potent inducer of the canonical NF-κB pathway, failed to 
increase NIK expression (see Figure 4D). Pre-translational regulation of NIK expression 
by TWEAK may be important for sustained activation of the noncanonical NF-κB 
pathway during the invasion process. TWEAK is synthesized in response to cellular 
injury and inflammation in tumor cells, as well as many cell types of the CNS, including 
neurons, microglia, and endothelial cells [140]. Therefore, TWEAK may function in 
both an autocrine and paracrine manner to robustly induce NIK expression, activate 
noncanonical NF-κB signaling, and increase MMP expression, thereby promoting tumor 
cell invasion. Overall, these data provide compelling evidence that the pathological, pro-
invasive effects of TWEAK are preferentially mediated by noncanonical NF-κB 
signaling. 
Recently, noncanonical NF-κB signaling was shown to promote glioma invasion 
in response to non-toxic doses of BV-6, a potential chemotherapeutic agent that 
promotes cancer cell death through antagonism of cellular Inhibitors of Apoptosis 
proteins (c-IAPs) [125]. Our data demonstrate that both basal, constitutive noncanonical 
NF-κB activity, as well as induction of noncanonical NF-κB signaling by an endogenous 
cytokine, TWEAK, play critical roles in promoting glioma invasion. According to our 
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findings, NIK is a critical mediator of TWEAK-induced glioma invasion. These findings 
demonstrate that noncanonical NF-κB signaling not only mediates therapy resistance, 
but also is important in the context of normal brain tumor pathogenesis. 
Lastly, it was recently reported that IKK-dependent, canonical NF-κB signaling 
suppresses NIK activity and noncanonical NF-κB signaling [141]. In the context of those 
findings, our data suggest that inhibition of canonical NF-κB pathway might result in 
increased constitutive noncanonical NF-κB activity, thereby promoting tumor cell 
invasion and pathogenesis. Notably, the ability of TWEAK to induce NIK expression 
and promote invasion is not only observed in glioma cells expressing high levels of 
RelB, but also in glioma cells with low levels of endogenous RelB expression (Figure 6). 
Altogether, these data suggest that blocking TWEAK signaling and noncanonical NF-κB 
activation, alone or in combination with inhibition of canonical NF-κB signaling, will be 
more efficacious for attenuation of tumor cell invasion and, therefore, have therapeutic 
value in a broad range of glioma subtypes. 
 
Conclusion 
Here, we establish a key role for noncanonical NF-κB signaling in glioma that is 
independent of the canonical NF-κB pathway. Specifically, we demonstrate that RelB 
promotes glioma invasion in the absence of RelA, and that TWEAK preferentially 
regulates noncanonical NF-κB signaling in glioma through a novel, signal-specific 
induction of NIK expression. Moreover, NIK is sufficient to promote brain tumor 
growth in vivo. To date, therapeutic strategies targeting NF-κB have focused almost 
exclusively on inhibition of the canonical NF-κB pathway [142]. Our findings provide a 
compelling rationale for considering TWEAK/FN14 and NIK inhibition as therapeutic 
strategies for aggressive glioma, as well as other highly invasive cancers. 
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Methods 
Cell culture & reagents 
BT lines obtained from glioma patients (BT25, BT114, BT116, BT132) were obtained as 
described previously [143]. 293 T, U87-MG, and U373 cells were purchased from 
ATCC. Glioma cell lines were cultured in DMEM/F12 + 10% FBS (1X Glutamax, 1X 
Pen/Strep) or Neural Stem Cell (NSC) medium (DMEM/F12, 1X B-27 Supplement 
minus Vitamin A, 1X Glutamax, 50 ng/ml EGF, 50 ng/ml bFGF, 1X Pen/Strep). All cell 
culture reagents were from Life Technologies (Grand Island, NY). rhTNFα was obtained 
from Promega (Madison, WI), and rhTWEAK was obtained from PeproTech (Rocky 
Hill, NJ). GM6001 inhibitor, MMP Inhibitor I, and MG132 inhibitor were obtained from 
EMD Millipore (Temecula, CA). 
 
3-D invasion assays 
Invasion assays were performed as described previously [28, 49]. In brief, Type I 
collagen extracted from rat tail tendons [144] was diluted to 2 mg/ml in DMEM/F12 (1X 
Pen/Strep) and matrices were polymerized in half-area 96-well plates. 40,000 cells per 
well were seeded in 100 μl DMEM/F12 (1x Pen/Strep, 1X Glutamax) without growth 
factors or serum. Cells were fixed with 3% glutaraldehyde solution after 48 h of invasion 
and stained with 0.1% toluidine blue. Invasion density was quantified by counting cells 
below the plane of the monolayer by bright-field light microscopy using a 10x10 ocular 
grid at 10x magnification corresponding to a 1-mm2 field. Numbers in equivalent fields 
were counted (n = 3 wells). Cross-sectional images were taken with an Olympus CKX41 
inverted microscope and Q-Color 3 camera. 
 
Western blots 
Whole-cell lysates were prepared using RIPA buffer with 1X Halt protease and 
phosphatase inhibitors (Thermo Scientific, Rockford, IL). Cytoplasmic and nuclear 
extracts were prepared as previously described [145]. 25-40 μg of protein was separated 
in replicate 9% polyacrylamide (29:1 Bis) Tris gels and transferred to replicate 
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nitrocellulose membranes for probing proteins in parallel. After transfer, gels were 
stained with GelCode Coomassie (Thermo Scientific, Rockford, IL) and scanned with 
the IR700 channel of an Odyssey Infrared Imaging system (LI-COR Biosciences, 
Lincoln, NE) for first verification of even protein loading. Westerns were performed by 
blocking membranes in 1:1 PBS/Odyssey Blocking Buffer (LI-COR Biosciences, 
Lincoln, NE) prior to co-incubation with mouse and rabbit primary antibodies. 
Simultaneous detection was performed using with goat anti-rabbit IRDye800CW and 
goat anti-mouse IRDye680 secondary antibodies (LI-COR Biosciences, Lincoln NE). 
Membranes were probed in parallel for simultaneous detection of multiple antibodies in 
replicate membranes without stripping. Western blots and Coomassie-stained gels were 
scanned with the Odyssey Imager. Color images were scanned with a LI-COR Infrared 
Imaging System, converted to black and white, and analyzed using the LI-COR Image 
Studio software. Quantitative analysis of indicated images was performed using Image 
Studio or Image J software (NIH, Bethesda, MA). The following Santa Cruz 
Biotechnology (SC, Santa Cruz, CA) and Cell-Signaling Technology (CST, Danvers, 
MA) antibodies were used: RelB (CST-4922), RelA (SC- 8008), Phospho-RelA Ser536 
(CST-3033), c-Rel (CST-4727), p100/p52 (CST-3017), p105/p50 (CST 13681), LaminA 
(SC 56137), IκBα (CST 4814), NIK (CST 4994), β-Actin (SC-69879). 
 
 
Plasmids 
pLenti6 overexpression constructs for RelB and NIK were generated by subcloning 
cDNA into pLenti6-V5-DEST (Addgene, Cambridge, MA) using the GATEWAYTM 
Cloning System. Luciferase (Promega, Madison, WI) or tagRFP (Evrogen, Moscow, 
Russia) coding sequences were subcloned into pLeni6-V5-DEST and used as controls 
for RelB and NIK overexpression. MissionTM Lentiviral shRNA plasmids for RelA, 
RelB and control were purchased from Sigma-Aldrich (St. Louis, MO). shRelB, as well 
as its control, was described previously as shRelB-3 [49]. shNFKB2, shNIK, and 
shControl oligonucleotides (Integrated DNA Technologies, Coralville, IA) were 
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subcloned into pLKO.1-puro (Addgene, Cambridge, MA). Exact sequences are available 
upon request. 
 
Lentivirus production and transduction 
293 T cells were transfected with 7 μg of lentiviral plasmids using 21 μg of 
polyethyleneimine (Polysciences Inc., Warrington, PA). Lentiviruses were harvested 
after 3 days and used to infect 2x105 glioma cells. Transduced cells were selected for 72 
h in DMEM/F12 NSC medium containing 0.6 μg/ml Puromycin or 3 μg/ml Blasticidin 
(Invivogen, San Diego, CA) to verify stable transduction. Cells were continuously 
selected during culture with 0.6 μg/ml Puromycin (shRNA constructs) and/or 6 μg/ml 
Blasticidin (overexpression constructs). 
 
Quantitative reverse-transcriptase PCR 
Total RNAs were isolated from cells using PurelinkTM RNA Mini Kit (Life 
Technologies, Carlsbad, CA). cDNA was synthesized from 1 μg of total RNA using 
SuperScript® III Reverse Transcriptase (Life Technologies, Carlsbad, CA) following 
manufacturer’s instructions. Quantitative RT-PCR was performed using SYBR® Green 
PCR Master Mix (Applied Biosystems, Foster City CA). Expression of mRNA was 
normalized to either GAPDH or RPLP0 expression levels. The following primers were 
used in amplifications: GAPDH 5′-AATGAAGGGGTCATTGATGG-3′, 5′-
AAGGTGAAGGTCGGAGTCAA-3′; RPLP0 5′- TCGTCTTTAAACCCCTGCGTG-3′, 
5′-TGTCTGCTCCCACAATGAAAC-3′; MMP-2 5′-AAGAAGTAGCTGTGACCGCC-
3′ 5′-TTGCTGGAGACAAATTCTGG-3′; MMP9 5′-GCACTGCAGGATGTCATAGG-
3′ 5′-ACGACGTCTTCCAGTACCGA-3′; MMP-14 5′-
TGCCTACCGACAAGATTGATG-3′ 5′-ATCCCTTCCCAGACTTTGATG-3′; NIK 5′-
TTCAGCCCCACCTTTTCAG-3′ 5′-ACGCTTTCCCTTCCAACAC-3′. All experiments 
were performed at least three times with three replicates per sample. 
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Orthotopic mouse xenografts 
All animal experiments were done in compliance with IACUC, AAALAC and Texas 
A&M University Health Science Center Biosafety guidelines using an IACUC-approved 
Animal Use Protocol (# 2012–174). For orthotopic tumor inoculations, cells were 
labeled using a DiD (DiIC18(5); 1,1′-dioctadecyl-3,3,3′,3′- 
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt) cytoplasmic membrane 
dye; abs/em = 644/655 (Biotium, Hayward, CA) according to the manufacturer’s 
directions. 0.5-1x106 cells in 3–5 μl phosphate buffered saline were injected into the 
right cortex of 4–6 week old CD-1 nude mice (n = 3 each). Tumor cells were imaged in 
vivo at indicated times post-injection using an IVIS Spectrum In Vivo Imaging System 
and Living Image Software (Perkin Elmer, Waltham, MA). Tumor volume was 
calculated from the formula: Volume = 0.5 x length x width2. The highest and lowest 
numbers for calculated tumor volume in each group were excluded from analysis. 
 
Statistical analyses 
GraphPad Prism 5 software was used for all statistical analyses. Unaired student’s t-test 
or one-way analysis of variance (ANOVA) with Tukey’s honest significant difference 
(HSD) post-test was performed and an α-value of 0.05 was used as criteria for statistical 
significance.  
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CHAPTER III  
 
META-ANALYSIS OF NCI PATIENT DATA INDICATES TWEAK AXIS 
EXPRESSION IS A NEGATIVE PROGNOSTIC INDICATOR 
 
Background 
Gliomas are the most common primary brain tumors in adults. High-grade gliomas, 
including Grade IV Glioblastoma, have an abysmal prognosis of approximately 15 
months median survival [7] due to inevitable recurrence following resection, radiation, 
and chemotherapy [4]. High-grade gliomas can occur de novo or progress from lower-
grade gliomas [2]. Gliomas demonstrate considerable heterogeneity of cellular origin, 
tumor infiltrates, differentiation status, and genomic aberrations [2, 10, 13], requiring 
comprehensive understanding and analysis of the multiple factors simultaneously. 
Additionally, clinical perspective and context are required to determine therapeutic value 
of basic science findings. 
To address these issues, multiple initiatives to make clinical and genome-wide 
microarray expression data for gliomas available have been developed by the National 
Cancer Institute (NCI), including The Cancer Genome Atlas (TCGA) [146] and the 
Repository of Molecular Brain Neoplasia Data (REMBRANDT) [23].  Using expression 
data, the confounding heterogeneous genetics of high-grade gliomas have been 
addressed by principle-component analysis and hierarchical clustering to identify distinct 
clinically-relevant subtypes in glioblastoma [11, 24]. Hierarchical clustering of TCGA 
data by Verhaak et al. resulted in four distinct subtypes named by convention from the 
literature and gene ontology of the signatures: Classical, Mesenchymal, Neural, and 
Proneural [24]. These published subtype signatures have been accepted by the Broad 
Institute as Gene Set Enrichment Analysis signatures and made publically available 
(Appendix B: Table B1). From these datasets, powerful tools have become publically 
available to contextualize basic science research within clinical outcomes and foster 
translational research. 
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TNF-like weak inducer of apoptosis (TWEAK) is the 12th member of the TNF 
superfamily of cytokines with gene designation TNSF12 [89]. TWEAK activation of its 
receptor FGF-inducible immediate-early response gene Number 14 (FN14, gene name 
TNFRSF12A) results in recruitment of TNF Receptor-Associated Factor 3 (TRAF3, gene 
name TRAF3) [111]. Under unstimulated conditions, TRAF3 acts as a negative regulator 
of constitutively active NF-κB-Inducing Kinase (NIK, gene name MAP3K14) and 
recruits an E3-ligase complex to constitutively degrade NIK [67]. NIK stabilization 
activates the noncanonical NF-κB pathway by IKKα activation, phosphorylation of p100 
(NFKB2), proteolytic processing of p100 to p52, and translocation of p52-RelB 
heterodimers to the nucleus [97]. TRAF3 recruitment to FN14 due to TWEAK 
engagement eliminates TRAF3 negative regulation of NIK [96]. TWEAK is therefore a 
ligand that acts upon its receptor (FN14) to activate a MAP3K (NIK) by receptor-
mediated engagement of a negative regulator of the MAP3K (TRAF3). We have 
designated this pathway the TWEAK Axis (Figure 8).  
 
 
Figure 8 The TWEAK Axis. Protein names for members of the TWEAK Axis are written in black. Gene 
names for the corresponding genes encoding these proteins are italicized in red. 
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Increased TWEAK and FN14 protein levels have been recently implicated in 
cancer, including gliomas, though activation of NF-κB [105, 106, 116]. NF-κB is a 
family of evolutionarily-conserved transcription factors RelA (RELA), RelB (RELB), c-
REL (REL), p105/p50 (NFKB1), and p100/p52 (NFKB2) that dimerize and activate gene 
transcription via their Rel Homology Domain (RHD). The canonical NF-κB pathway 
can be activated by Tumor Necrosis Factor alpha (TNFα, TNF) activating its receptor 
TNF Receptor 1 (TNFR1, TNFSFR1A) to activate the Inhibitor of nuclear factor Kappa-
B Kinase (IKK) heteotrimeric complex (IKKα, IKKβ, IKKγ). IKKγ (IKBKG) acts as a 
scaffold for IKKα (Conserved Helix-Loop-Helix Ubiquitous Kinase CHUK) and IKKβ 
(IKBKB). IKKβ phosphorylates Inhibitor of Kappa-Beta alpha (IκBα, NFKBIA), which 
sequesters RelA/p50 heterodimers in the cytoplasm. Phosphorylation of IκBα triggers 
proteasomal-degradation of IκBα and liberation of RelA/p50 heterodimers to translocate 
to the nucleus and effect gene transcription. The noncanonical NF-κB pathway can be 
activated by TWEAK (TNFSF12) activating its receptor FN14 (TNFRSF12A), which 
recruits TRAF3 (TRAF3), (see Figure 8). Recruitment of TRAF3 to the cytoplasmic tail 
of FN14 removes its negative regulation of NIK (MAP3K14) via protein-protein 
interaction. Without TRAF3, NIK is able to phosphorylate and form a trimeric complex 
with 2 IKKα (CHUK) homodimers. The NIK-IKKα complex phosphorylates p100 
(NFKB2) for partial degradation to p52. RelB (RELB) sequestered in the cytoplasm due 
to interaction with p100 is then able to form a heterodimer complex with p52, translocate 
to the nucleus, and effect gene transcription. c-Rel (REL) is able to heterodimerize with 
other NF-κB transcription factors, though its specific functions are poorly understood.  
We have recently shown a significant biological function of TWEAK in the 
specific activation of noncanonical NF-κB signaling and increased invasion in high-
grade glioma cells [50]. In this study, we investigate expression of TWEAK Axis genes 
MAP3K14, TRAF3, TNFSF12, and TNFRSF12A in patient glioma samples using a large 
cohort of gene expression and clinical data from NCI repositories to determine 
correlations with prognostic factors, NF-κB genes, and glioma subtypes. 
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Results 
Tumor and patient clinical data is representative of glioma patients 
Because of the considerable genetic and cellular complexity of gliomas as well as the 
dismal prognosis despite years of advances, the NCI has developed considerable 
initiatives to make genome-wide expression and clinical data available to basic science 
researchers. We sought to determine clinical relevance of the TWEAK Axis using 
microarray gene expression data accessed from the NCI databases TCGA and 
REMBRANDT [23, 146]. Probesets were background-corrected, averaged for each 
gene, normalized, and median-centered for each dataset. In all, 1153 samples with 883 
accompanying clinical information were utilized for subsequent analysis (Appendix B: 
Table B2).  To validate our datasets versus previous cohorts and findings, we 
investigated the accompanying glioma clinical data of the TCGA and REMBRANDT 
datasets for trends in overall survival by age, sex, grade, histologic type, and Verhaak et 
al. subtype. Median age at initial diagnosis was 56 years old, consistent with previous 
reports [10]. Overall survival (days to death) decreased as a function of age with the 
exception of poor prognosis in pediatric patients ages 10-19 (Figure 9A), which has been 
noted in the literature [10]. The ratio of male to female glioma patients was 1.64, 
consistent with previous reports [10, 147]. Overall survival was higher in female patients 
(Figure 9B), though this difference did not achieve statistical significance (Males: Mean 
543.3, SEM 35.01, n = 329; Females: Mean 673.3, SEM 62.78, n = 202; t(529) = 1.872, 
p = 0.062). From one-way ANOVA with Tukey’s HSD post-test, we confirmed that 
overall survival was significantly reduced in glioblastoma patients (Grade IV Mean 
500.6, SEM 23.06, n = 562) versus lower grades (Grade II Mean 1421, SEM 153.1, n = 
94, p < 0.0001; Grade III Mean 1251, SEM 161.3, n = 74, p < 0.0001), (Figure 9C). 
Median survival in glioblastoma was 372 days, consistent with previous reports [6]. 
Glioblastoma had a significantly worse overall survival (Mean 500.6, SEM 23.06, n = 
562, p < 0.0001) versus other histological glioma types astrocytoma (Mean 1334, SEM 
128, n = 111, p < 0.0001), oligodendroglioma (Mean 1331, SEM 227.7, n = 50, p < 
0.0001), and mixed (Mean 1584, SEM 514.9, n = 9, p < 0.0001) (Figure 9D).  A more  
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Figure 9 TCGA and REMBRANDT samples’ clinical data are representative of glioma patients. (A) 
Overall survival stratified by age range. Data represent average overall survival in days ± SEM. (B) 
Overall survival between male and female patients. Data represent average overall survival in days ± 
SEM. (C) Overall survival stratified by tumor grade. Data represent average overall survival in days ± 
SEM. *p < 0.001 using One-way ANOVA with Tukey’s HSD post-test. (D) Overall survival stratified by 
histologic type. Data represent average overall survival in days ± SEM. *p < 0.001 using One-way 
ANOVA with Tukey’s HSD post-test. (F) Kaplan-Meier plots from microarray data, stratified by subtype. 
Data represent percent survival of the cohort as a function of days. C–Classical, M–Mesenchymal, N-
Neural, P–Proneural.  (G) Summary table of Kaplan-Meier survival plots by subtype. Data represent 
median survival in days and number of deaths per subtype. *p < 0.05, ***p < 0.001 using the Log-Rank 
test. 
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Figure 9 TCGA and REMBRANDT samples’ clinical data are representative of glioma patients.  
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favorable outcome with oligodendroglioma has been reported [10], but was not observed 
in our dataset. There was no significant difference in survival between glioblastoma and 
mixed glioma (Mean 381, SEM 537.2, n = 7).  
Next, we sought to describe our dataset using recently identified glioblastoma 
subtypes from clustering by Verhaak et al. [24]. Classification of tumor samples 
according to Verhaak et al. glioblastoma subtypes was determined by calculating the 
percent enrichment of each subtype gene set published by Verhaak et al. and listed in 
Appendix B: Table B1. Percent enrichment was determined by counting how many of 
the genes in a subtype gene set were upregulated divided by the number of genes in the 
set. Setting the upregulation threshold at conventional 2-fold significance resulted in 
very low enrichment percentage scores deemed undependable. Setting the threshold to 
indicate any upregulation of subtype genes resulted in enrichment percentage scores 
determined primarily by the number of genes in the subtype classification set. 
Agreement in subtype classification was observed between 1.5-fold and 1.75-fold 
upregulation (data not shown), therefore a more-strict 1.75-fold upregulation criterion 
was used for calculating percent enrichment scores to classify samples by Verhaak et al. 
subtype. The classification program was verified by confirming differential expression 
of known subtype markers Epidermal Growth Factor Receptor (EGFR), Chitanse-3-Like 
Protein 1 (CHI3L1), Myelin Basic Protein (MBP), and Oligodendrocyte Transcription 
Factor 2 (OLIG2) (Appendix A: Figure A5). Each of the subtype markers was 
significantly increased in its respective subtype versus the other subtypes. 
Patients in the Proneural subtype group had a significantly higher average overall 
survival (Mean 1021, SEM 87.1, n = 179) versus Classical subtype (Mean 549.1, SEM 
51.0, n = 147, p < 0.001), Mesenchymal subtype (Mean 579.1, SEM 47.9, n = 228, p < 
0.001), and Neural subtype (Mean 729.8, SEM 81.2, n = 154, p < 0.05) groups (Figure 
9E). Further survival analysis on gliomas stratified by subtype indicated a significant 
difference in Kaplan-Meier survival in the Proneural subtype versus the other subtypes 
(Figure 9F). Median survival was greatest in the Proneural subtype group  
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and lowest in the Mesenchymal subtype group (Figure 9G), supporting the convention 
that genetic profiling of gliomas highlights different clinical entities. Together these 
analyses indicate that the combined TCGA and REMBRANDT dataset is representative 
of glioma patients and distributed equally among genetic subtypes. 
 
The TWEAK Axis is differentially expressed in gliomas by age, grade, type, and 
subtype 
Gender, age, grade, and histologic type have been identified as significant factors in the 
prognosis of gliomas [10]. Reports of stratifying tumors by subtype have proposed 
conflicting data whether Proneural or Mesenchymal subtypes have a poorer prognosis 
[11, 24]. To identify differences in TWEAK Axis expression, we compared expression 
of MAP3K14, TRAF3, TNFSF12, and TNFRSF12A and determined statistical relevance 
of TWEAK Axis expression within subsets of these prognostic indicators. 
First, dataset samples were stratified by gender. There was no significant 
difference in expression of TWEAK Axis genes between male and female patients (data 
not shown).  
Second, dataset samples were stratified by age at initial diagnosis (Figure 10). No 
significant difference in MAP3K14 expression (Figure 10A) or TRAF3 expression 
(Figure 10B) was observed between age groups. Both TNFSF12 expression (Figure 10C) 
and TNFRSF12A expression (Figure 10D) were significantly lower in the 20-29 years 
and 30-39 years group versus higher age groups except for 80-89 years. TNFSF12 and 
TNFRSF12A expression was lower in the 80-89 years group versus 40-49, 50-59, 60-69, 
and 70-79 years groups, though this was not significant. Sample size, average, and SEM 
are summarized in Figure 10E. Altogether, MAP3K14 and TRAF3 expression did 
notvary by age, but TNFSF12 and TNFRSF12A expression were lowest in age ranges 
with the best prognosis (see Figure 9A).  
Third, dataset samples were stratified by histologic grade (Figure 11). 
Stratification by grade indicated a significant increase in expression of MAP3K14 
(Figure 11A), TNFSF12 (Figure 11C), and TNFRSF12A (Figure 11D) in glioblastomas  
 44 
 
 
Figure 10 Expression of TWEAK Axis genes stratified by age range. (A) MAP3K14, (B) TRAF3, (C) 
TNFSF12, and (D) TNFRSF12A expression values from microarray data. Data represent median log2 
expression with boxes indicating upper and lower quartile and whiskers indicating range. **p < 0.01, ***p 
< 0.001 relative to 20-29 years; #p < 0.05, ##p < 0.01, ###p < 0.001 relative to 30-39 years using Kruskal-
Wallis test with Dunn’s post-test. (E) Summary table of TWEAK Axis expression within age groups. Data 
represent average log2 expression ± SEM.  
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(Grade IV) versus Grade II gliomas. TRAF3 expression was not significantly different 
between groups (Figure 11B). A significant increase in TNFSF12 expression was 
observed between Grade III gliomas and Grade IV gliomas (Figure 11C). TNFRSF12A 
expression in Grade III gliomas was significantly increased versus Grade II gliomas 
(Figure 11D). Sample size, average, and SEM are summarized in Figure 11E. Together 
these data indicate a progressive increase in TNFSF12 and TNFRSF12A expression with 
increasing glioma grade.  
Fourth, samples were stratified by histologic type (Figure 12). Stratification by 
histologic type indicated a significant increase in expression of MAP3K14 (Figure 12A), 
TNFSF12 (Figure 12C), and TNFRSF12A (Figure 12D) in glioblastomas (Grade IV) 
versus oligodendrogliomas. TNFSF12 expression was also significantly different 
between astrocytomas and oligodendrogliomas (Figure 12C). No significant difference 
in TRAF3 expression was observed between histologic types (Figure 12B). TNFSF12 
and TNFRSF12A expression was significantly increased in glioblastomas versus 
astrocytomas (Figure 12C, D). Additionally, there was a significant increase in 
TNFRSF12A expression in oligodendrogliomas versus mixed gliomas (Figure 12D). 
Sample size, average, and SEM are summarized in Figure 12E. Together, these data 
indicate increased expression of TWEAK Axis Genes in astrocytic-lineage cancers 
versus pure oligodendrogliomas. 
Finally, samples were stratified into the four glioblastoma subtypes proposed by 
Verhaak et al. 2010 [24] (Figure 13).  Stratification by Verhaak et al. subtype 
demonstrated considerable variability in expression of the TWEAK Axis genes. 
MAP3K14 was comparable between Classical and Mesenchymal subtypes as well as 
between Neural and Proneural subtypes (Figure 13A). MAP3K14 expression was  
significantly higher in both Classical and Mesenchymal versus Neural and Proneural 
subtypes (Figure 13A). TRAF3 expression was highest in the Neural subtype, with 
median expression indicating slight upregulation of TRAF3 (Figure 13A). Surprisingly, 
TRAF3 expression was significantly different between all subtypes except for Classical 
and Proneural subtypes (Figure 13B). TNFSF12 expression was the most variable of the  
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Figure 11 Expression of TWEAK Axis genes stratified by tumor grade. (A) MAP3K14, (B) TRAF3, 
(C) TNFSF12, and (D) TNFRSF12A expression values from microarray data. Data represent median log2 
expression with boxes indicating upper and lower quartile and whiskers indicating range. **p < 0.01, ***p 
< 0.001 using Kruskal-Wallis test with Dunn’s post-test. (E) Summary table of TWEAK Axis expression 
within tumor grade. Data represent average log2 expression ± SEM. 
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Figure 12 Expression of TWEAK Axis genes stratified by histologic type. (A) MAP3K14, (B) TRAF3, 
(C) TNFSF12, and (D) TNFRSF12A expression values from microarray data. Data represent median log2 
expression with boxes indicating upper and lower quartile and whiskers indicating range. *p < 0.05, **p < 
0.01, ***p < 0.001 using Kruskal-Wallis test with Dunn’s post-test. (E) Summary table of TWEAK Axis 
expression within histologic type. Data represent average log2 expression ± SEM. 
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TWEAK Axis and statistically significant different between all subtypes (Figure 13C). 
TNFSF12 expression was highest in the Mesenchymal subtype, decreasing in the Neural, 
Classical, and Proneural subtypes. Similar to the trend seen in MAP3K14 expression, 
TNFRSF12A expression was significantly higher in both Classical and Mesenchymal 
versus Neural and Proneural subtypes (Figure 13D). Sample size, average, and SEM are 
summarized in Figure 13E. Overall, gene expression levels of the TWEAK Axis were 
highest in the Mesenchymal subtype, comparable between the Mesenchymal and 
Classical subtypes, and lowest in the Proneural subtype. 
 
Expression of the TWEAK Axis correlates with canonical and noncanonical NF-κB 
expression 
Aberrant NF-κB signaling has been widely implicated in glioma, though the majority of 
studies focus on the canonical NF-κB pathway. Our lab has shown that noncanonical 
NF-κB signaling contributes to glioma proliferation, differentiation, and invasion [49]. It 
has become apparent that both NF-κB pathways must be considered in glioma. To 
elucidate roles of both pathways in TWEAK Axis signaling, gene expression values for 
MAP3K14, TRAF3, TNFSF12, and TNFRSF12A were correlated with gene expression 
values of NF-κB genes from both pathways (Table 1). Most comparisons indicated 
significant but very weak or weak correlations between TWEAK Axis genes and NF-κB 
genes. TRAF3 was only very weakly correlated with NF-κB genes. All four TWEAK 
Axis genes were more positively correlated with RELB expression than RELA 
expression. Expression of MAP3K14 and TNFSF12 only weakly correlated with RELB 
expression, whereas TNFRSF12A expression moderately correlated with RELB 
expression. Additionally, expression of the four TWEAK Axis genes correlated more 
positively with expression of IKBKB and NFKB1 than CHUK and NFKB2 expression. 
MAP3K14 and TNFRSF12A expression had moderate correlation with IKBKB 
expression and weak correlation with NFKB1 expression. Within the TWEAK Axis, 
TNFRSF12A expression had weak correlation with MAP3K14 expression. TNFSF12 and 
its receptor TNFRSF12A were weakly correlated. TWEAK Axis expression was also   
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Figure 13 Expression of TWEAK Axis genes stratified by glioblastoma subtype. (A) MAP3K14, (B) 
TRAF3, (C) TNFSF12, and (D) TNFRSF12A expression values from microarray data. Data represent 
median log2 expression with boxes indicating upper and lower quartile and whiskers indicating range. *p 
< 0.05, **p < 0.01, ***p < 0.001 using Kruskal-Wallis test with Dunn’s post-test. (E) Summary table of 
TWEAK Axis expression within glioblastoma subtype. Data represent average log2 expression ± SEM. 
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Figure 13 Expression of TWEAK Axis genes stratified by glioblastoma subtype. 
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Table 1 Spearman’s ρ-values for TWEAK Axis and NF-κB gene expression 
NF-κB 
Gene 
Protein (C/NC) MAP3K14 TRAF3 TNFSF12 TNFRSF12A 
REL c-Rel 0.166*** 0.120*** 0.272 0.150*** 
RELA RelA - C 0.266*** 
-
0.146*** 
-0.010 0.238*** 
RELB RelB - NC 0.376*** 0.145*** 0.398*** 0.528*** 
NFKB1 p105/p50 - C 0.331*** 0.136*** 0.285*** 0.383*** 
NFKB2 p100/p52 - NC 0.236*** 
-
0.149*** 
0.180*** 0.268*** 
CHUK IKKα – C, NC -0.081** 0.139*** -0.064* -0.091** 
IKBKB IKKβ - C 0.410*** 
-
0.104*** 
0.264 0.410*** 
IKBKG IKKγ - C 0.151*** -0.019 0.150*** 0.132*** 
NFKBIA IκBα - C 0.245*** 0.026 0.187*** 0.083** 
MAP3K14 NIK - NC 1.000*** -0.133 0.153*** 0.318*** 
TNF TNFα – C, NC 0.112*** 0.085** 0.230*** -0.070* 
TNFRSF1A TNFR1 – C, NC 0.422*** -0.065* 0.487*** 0.720*** 
TNFSF12 TWEAK – C, NC 0.153*** 0.064* 1.000*** 0.288*** 
TNFRSF12A FN14 – C, NC 0.318*** 
-
0.148*** 
0.288*** 1.000*** 
NF-κB pathways: C–Canonical NF-κB, NC–Noncanonical NF-κB; *p < 0.05, **p < 0.01, ***p < 0.001 
 
 
 
correlated with expression of TNF and its receptor TNFRSF1A. Correlation was weak 
between TNFSF12 and TNF expression. There was a strong correlation between 
TNFSF12A and TNFSF1A expression, consistent with reports that FN14 and TWEAK 
are induced by tissue damage [102]. Together, these data indicate a complex relationship 
in the expression and regulation of NF-κB genes and the TWEAK Axis. 
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Expression of the TWEAK Axis correlates with mesenchymal GBM subtype 
We have demonstrated that TWEAK signaling activates of the noncanonical NF-κB 
pathway [50] (see Figure 4) and that noncanonical NF-κB transcriptional activity control 
expression of Mesenchymal subtype gene CHI3L1 and Proneural subtype gene OLIG2 in 
high-grade gliomas [49]. To explore context of TWEAK signaling in glioma subtypes, 
gene expression values for MAP3K14, TRAF3, TNFSF12, and TNFRSF12A were 
correlated with gene expression values for major markers identified within Classical, 
Mesenchymal, Neural, and Proneural subtype genes (Table 2) categorized by Phillips et 
al. and Verhaak et al. [11, 24]. TWEAK Axis genes were only very weakly correlated 
with Classical subtype marker EGFR. MAP3K14, TRAF3, and TNFSF12 had a very 
week correlation with Neural subtype maker MBP. TNFRSF12A correlation with MBP  
was negative and weak. Of the genes selected for correlation, MAP3K14, TNFSF12, and 
TNFRSF12A were most positively correlated with expression of the Mesenchymal 
subtype gene CHI3L1. MAP3K14 was weakly correlated with CHI3L1 and Collagen 
Type 1 α1 (COL1A1) and only very weakly correlated with other Mesenchymal subtype 
genes. TRAF3 was only very weakly correlated with glioma genes from the subgroups 
except for a weak negative correlation with Sex-determining-region Y-Box 2 (SOX2). Of 
the four TWEAK Axis genes, TNFRSF12A expression was most positively correlated 
with Mesenchymal subtype genes MET, CHI3L1, and COL1A1 as well as pro-invasive 
marker MMP9. Both TNFSF12 and TNFRSF12A had a low correlation with MET.  
Expression of TNFRSF12A was moderately correlated with RELB and strongly 
correlated with TNFRSF1A (see Table 1), both of which have been identified as 
upregulated in the Mesenchymal subtype [24]. TNFSF12 had a moderate negative 
correlation with OLIG2 and a weak negative correlation with SOX2, both of which are 
Proneural subtype markers. Together, these data indicate that TWEAK Axis expression 
correlate more positively with expression of Mesenchymal subtype genes than Classical, 
Neural, or Proneural subtype genes. 
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Table 2 Spearman’s ρ-values for TWEAK Axis and subtype expression 
Gene Protein (C/M/N/P) MAP3K14 TRAF3 TNFSF12 TNFRSF12A 
EGFR EGFR - C 0.151*** -0.115*** -0.052 0.035 
MET c-MET (HGFR) - M -0.016 0.084** 0.305*** 0.315*** 
CHI3L1 CHI3L1/YKL40 - M 0.331*** --0.058 0.473*** 0.688*** 
MBP MBP - N -0.153*** 0.195*** 0.145*** -0.295*** 
SOX2 SOX2 - P 0.107*** -0.297*** -0.432*** -0.116*** 
OLIG2 OLIG2 - P -0.164*** -0.085** -0.378*** -0.305*** 
COL1A1 Collagen Type 1 α1 - M 0.236*** 0.055 0.292*** 0.535*** 
MMP9 MMP9 - Invasion 0.138*** -0.021 0.135*** 0.423*** 
Markers for: C-Classical, M-Mesenchymal, N-Neural, P-Proneural; *p < 0.05, **p < 0.01, ***p < 0.001 
 
 
 
Increased MAP3K14, TNFSF12, and TNFRSF12A expression negatively impacts 
survival 
We have demonstrated that overexpression of NIK is sufficient to increase tumor 
volume in mice (See Figure 6). Additionally, previous data have shown high FN14 
levels are a negative prognostic factor [105]. We therefore investigated whether 
expression of MAP3K14, TRAF3, TNFSF12, or TNFRSF12A in the NCI datasets 
correlated with patient outcome. Patient samples with accompanying clinical 
information including overall survival (n = 879 samples) were ranked by gene 
expression of the TWEAK Axis genes. For each gene, samples were divided into 
quartiles (n = 220 per group) and overall survival values within each quartile were 
graphed using Kaplan-Meier survival curves (Figure 14). Overall survival was 
significantly improved in MAP3K14 between the lowest and highest quartile (Figure 
14A). Although survival and TRAF3 trended more positively by increased quartile 
(Figure 14B), there was no significant difference between quartiles. The lowest quartile 
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of TNFSF12 expression had a significantly better overall survival versus each of the 
other quartiles (Figure 14C). Similarly, the lowest quartile of TNFRSF12A expression 
had a significantly better overall survival versus each of the other quartiles (Figure 14D), 
as well as significantly better overall survival between the second and fourth quartile. In 
general, increased expression of TWEAK Axis genes by quartile reflected a decrease in 
median survival (Figure 14E). From these data, patients with higher expression of 
MAP3K14, TNFSF12, and TNFRSF12A had a worse overall survival than patients with 
lower expression, suggesting a negative prognostic role for TWEAK Axis in the clinical 
outcome of glioma patients. 
 
Discussion 
Increased expression and activation of the noncanonical NF-κB has been identified in 
high-grade gliomas and shown to increase proliferation and invasion. However, 
noncanonical NF-κB-specific extracellular signals in autocrine, juxtacrine, or paracrine 
signaling within a brain tumor are not well-understood. We have shown that 
extracellular TWEAK can activate the noncanonical NF-κB pathway and increase 
invasion [50]. Whether this significant biological response is relevant in a clinical 
context is not clear. We show that clinical and microarray data in NCI-curated databases 
TCGA and REMBRANDT are representative of patient demographics and prognosis  
(Figure 9) and represent a bona fide clinical cohort for our analysis of the TWEAK  
AXIS at the gene and clinical levels. 
Interestingly, we observed that of the TWEAK Axis genes, the ligand TWEAK 
(TNFSF12) and its receptor FN14 (TNFRSF12A) are the most differentially expressed 
among tumor samples and were expressed lowest in groups with better prognoses.  
TNFSF12 and TNFRSF12A expression was lowest in the younger non-pediatric age 
groups with better prognosis (Figure 10C, D).  TNFSF12 and TNFRSF12A expression 
increased with progressive tumor grade (Figure 11C, D). In addition to increasing with 
grade, TNFSF12 and TNFRSF12A expression was higher in glioblastoma versus lower- 
grade gliomas (Figure 11C,D, Figure 12C,D), indicating that expression of TNFSF12  
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Figure 14 Overall survivals within quartiles of TWEAK Axis gene expression. (A) MAP3K14, (B) 
TRAF3, (C) TNFSF12, and (D) TNFRSF12A Kaplan-Meier plots from microarray data, stratified by 
quartile. Data represent percent survival of the cohort as a function of days. (E) Summary table of 
TWEAK Axis Kaplan-Meier survival plots by quartile. Data represent median survival in days and 
number of deaths per quartile. *p < 0.05, **p < 0.01, ***p < 0.001 using the Log-Rank test. 
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and TNFRSF12A may be closely related to gliomagenesis and tumor progression. High-
grade gliomas have higher incidence at later age groups, which may account for some of 
the prognostic indications between TNFSF12 and TNFRSF12A expression in patient age 
and tumor grade. In contrast, MAP3K14 expression was only differentially expressed in 
Grade IV Mesenchymal subtype gliomas (Figure 11A, Figure 13A). While 
overexpression of MAP3K14 may be rarely observed in early pathogenesis of gliomas, 
normal levels of NIK mRNA for constitutive translation may still be important in later 
progression of gliomas as reflected by a significantly poorer survival in the highest 
quartile of MAP3K14 expression (Figure 14A).  Extrinsic dependence on TWEAK to 
activate cell signaling may therefore be an earlier or more significant event than 
increased intrinsic activity of the cells by overexpressing NIK. Taken together, this 
highlights therapeutic potential for targeting interactions of TWEAK and FN14. 
  Both the canonical and noncanonical NF-κB pathways can be activated by 
TWEAK depending on whether TWEAK is membrane-bound or soluble at high or low 
concentrations [94]. We show that MAP3K14, TNFSF12, and TNFRSF12A correlate 
with both canonical and noncanonical NF-κB genes (Table 1), though their biological 
significance is unclear. Expression of MAP3K14, TNFSF12, and TNFRSF12A was more 
strongly correlated with noncanonical NF-κB transcription factor RELB than either REL 
or canonical NF-κB transcription factor RELA. RELB expression has been shown as 
enriched in the invasive Mesenchymal subtype [24] and increased protein levels increase 
glioma invasion [49, 50]. The strongest correlation was between TNFRSF1 and 
TNFRSF12A expression (ρ = 0.720). The interaction between TWEAK and TNF 
signaling and their receptors has been recently studied in induction of keratinocyte 
apoptosis [148], though induction of TNFRSF1 and TNFRSF12A expression by their 
ligands has not been demonstrated in glioma. More direct analysis will be required to 
determine whether this correlation is through biologic signaling of TWEAK and TNFα 
or due to differential expression of TNFRSF1 and TNFRSF12A within enrichment of 
mesenchymal genes. 
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Finally, correlation of TWEAK Axis genes with Verhaak et al. subtype genes 
and stratification of tumor samples by subtype provided key insight into differential 
expression of the TWEAK Axis. Prominent genes EGFR from the Classical subtype and 
OLIG2 from the Neural subtype correlated only weakly with TWEAK Axis expression 
(see Table 2). TNFSF12 and TNFRSF12A correlated negatively with Proneural markers 
OLIG2 and SOX2, indicating that TWEAK signaling is distinctly downregulated in the 
Proneural subtype. In comparison to EGFR, OLIG2, and SOX2, TNFSF12 and 
TNFRSF12A were more positively correlated with the Mesenchymal subtype gene MET, 
an oncogene often amplified in glioblastoma and associated with invasion [11, 149]. 
Moderate gene expression correlations between mesenchymal genes and TNFSF12 and 
TNFRSF12A indicate that TWEAK and its receptor are differentially expressed in the 
mesenchymal subtype. Moderate to strong correlation was observed between TNFSF12 
and TNFRSF12A and the well-studied mesenchymal marker CHI3L1, which we have 
shown is regulated by RelB in glioma [49]. The aggressive invasive and recurrent 
natures of the Mesenchymal glioma subtype present considerable obstacles in improving 
outcome for glioma patients. TNFSFR12 was moderately correlated with expression of 
MMP9, a well-studied marker for invasion and poor prognosis in cancer [39]. TWEAK 
has been shown to induce MMP9 expression, and this may be primarily dependent on 
expression and activation of its receptor [95]. Additionally, TNFRSF12A expression 
moderately correlated with expression of COL1A1, a pathological substrate in brain 
tumors that facilitates invasion in the brain [47].  
Subtype analysis revealed that MAP3K14 and TNFRSF12A expression were 
comparable between Classical and Mesenchymal subtypes and between Neural and 
Proneural subtypes, though interestingly expression was significantly different than each 
subtype in the other pair (see Figure 13). These “tiers” may represent increasing 
MAP3K14 and TNFRSF12A expression in less differentiated tumors. TNFSF12 
expression was highest in the Mesenchymal subtype group and significantly 
differentially-expressed between all subtype groups. This could reflect either a role for 
TWEAK signaling in maintaining distinct subtypes or that the subtype genetic landscape 
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of tumors predisposes the tumors to TWEAK signaling. In contrast to Mesenchymal 
subtype tumors, Proneural subtype tumors reflected the greatest survival (see Figure 9), 
which may indicate initial tumors versus recurrent tumors that relapse as mesenchymal 
[11]. Additionally, Proneural subtype tumors had the lowest TNFSF12 and TNFRSF12A 
expression of the four subtypes, the second-lowest MAP3K14 expression, and the 
highest expression of TRAF3 (see Figure 13). These data are consistent with increased 
survival in the low quartiles of MAP3K14, TNFSF12, and TNFRSF12A and the highest 
quartiles of TRAF3 (see Figure 14). Altogether, these data suggest that the TWEAK Axis 
is differentially expressed and most relevant in a subset of more-fatal tumors, supporting 
anti-TWEAK therapy as a more viable strategy in the treatment of high-grade gliomas 
than low-grade gliomas.  
 
Conclusion 
Here, we report a modest but statistically significant increase in TWEAK Axis gene 
expression within subsets of tumors with poorer prognosis. Specifically, we demonstrate 
that statistical analysis of MAP3K14, TRAF3, TNFSF12, and TNFRSF12A in a validated 
dataset indicated differential expression of MAP3K14, TNFSF12, and TNFRSF12A in 
groups stratified by prognostic indicators including age at diagnosis, tumor grade, tumor 
histologic type, and glioma subtype. MAP3K14, TNFSF12, and TNFRSF12A were more 
highly expressed in groups of these factors associated with poorer prognosis. Moreover, 
Kaplan-Meier survival analysis determined that groups with increased expression of 
these genes had significantly decreased survival. MAP3K14, TNFSF12, and 
TNFRSF12A expression correlated most positively with NF-κB signaling genes IKBKB, 
RELB, and TNFRSF1A as well as mesenchymal subtype genes CHI3L1 and COL1A1. 
The TWEAK Axis was differentially expressed in glioma subtypes and most enriched in 
the Mesenchymal subtype. Our findings provide a compelling rationale for investigating 
inhibition of the TWEAK Axis as a viable therapeutic strategy in the treatment of high-
grade invasive gliomas, particularly in the Mesenchymal subtype. 
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Methods 
Datasets 
Raw and processed samples files were downloaded from the TCGA Data Portal and 
ArrayExpress Archive. Dataset sources, glioma grade, numbers of samples, sample 
platforms, and normalization/scaling methods are summarized in Appendix B: Table B2. 
All files were loaded into GeneSpring GX software (Agilent Technologies, Santa Clara 
CA) for analysis. Data from each platform were normalized and centered separately. 
Probesets for the Affymetrix platform were normalized using Robust Multichip Analysis 
(RMA) [150]. Probesets for the Agilent two-color platform were normalized using 
Locally Weighted Scatterpoint Smoothing (LOWESS) [151]. Probesets were averaged 
for each gene. Gene-level expression values were transformed to 2-based logarithm scale 
and baseline transformed around the median for each dataset using GeneSpring GX 
software. Gene expression values for replicate patient samples within a technology were 
averaged. Entrez Gene ID was used to match genes between microarray technologies. 
Entrez Gene IDs are listed in Appendix B: Table B3.  
 
Determination of Verhaak subtype for glioma samples 
Samples were classified by GSEA according to Classical-Mesenchymal-Neural-
Proneural glioblastoma subtype genes published by Verhaak et al. [24] and listed in 
Appendix B: Table B1 using an R script (available on request). In short, each gene in the 
subtype list that was expressed above a threshold of log2-base value of 0.807 (1.75-fold 
upregulated) was counted. Each patient sample was assigned an enrichment percentage 
score for each subtype based on the percentage of genes in each subtype list that were 
upregulated. Samples were designated as Classical, Mesenchymal, Neural, or Proneural 
determined by the highest subtype percentage score.  
 
Statistical analysis for gene expression and overall survival 
GraphPad Prism 5 software was used for all statistical analyses. Mann-Whitney U or 
Kruskal-Wallis with Dunn’s post-test was used to assess statistical significance between 
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log2-base gene expression data. Survival data in months was converted to days by 
multiplying by 30.4, the average number of days per month. Unpaired student’s t-test or 
One-way analysis of variance (ANOVA) with Tukey’s Honest Significant Difference 
(HSD) post-test was performed to establish statistical significance for days to death 
survival analysis. An α-value of 0.05 was used as criteria for statistical significance. 
 
Correlation for gene expression 
 
Correlation values between genes were determined using Spearman’s rank correlation 
coefficient (ρ). Correlations were described using the Evans convention [152]: very 
weak (0 ≤ ρ < 0.2), weak (0.2 ≤ ρ < 0.4), moderate (0.4 ≤ ρ <0.6), strong (0.6 ≤ ρ < 0.8), 
or very strong (0.8 ≤ ρ ≤ 1). An α-value of 0.05 was used as criteria for statistical 
significance. 
 
Kaplan-Meier survival analysis 
Gene expression values for samples with clinical data were ranked and grouped by 
quartile (n = 220 per group). Patient mortality events within each quartile were used to 
generate Kaplan-Meier curves were generated in GraphPad Prism 5. Statistical 
significance between curves was determined using the Log-Rank (Mantel-Cox) Test. An 
α-value of 0.05 was used as criteria for statistical significance. 
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CHAPTER IV  
CONCLUSIONS AND RECOMMENDATIONS 
 
Due to our limitations of understanding the complex nature of high-grade 
gliomas, the prognosis with current aggressive conventional therapy of maximal 
resection, high-dose radiation, and chemotherapy is still an abysmal 15 months median 
survival. Improvements in temozolomide chemotherapy and radiation have meagerly 
improved the prognosis by a few months [6]. Thus, high-grade gliomas are one of the 
most deadly incurable forms of cancers. Sophisticated gene-array and statistical analyses 
aiming to account for and understand clinically-relevant mutations and differential 
expression have increased rather than decreased the perceived complexity of high-grade 
gliomas [11, 13, 22, 24]. To this end, we believe pathways identified to be clinically 
relevant to high-grade gliomagenesis must be evaluated biologically to understand 
molecular contributions of these genes and proteins in the phenotype of glioma. From 
the greater scope of research that precedes it, we have focused our efforts on advancing a 
molecular-biology understanding of the noncanonical NF-κB pathway and its activation 
by TWEAK in glioma invasion. Although understanding of NF-κB in the pathogenesis 
of high-grade gliomas has been developed following decades of insight into canonical-
NF-κB signaling, we show in this work that noncanonical NF-κB is differentially 
expressed in invasive glioma cells and can be specifically activated by extracellular 
signals to promote invasion. From this, we provide a rationale for considering both the 
canonical and noncanonical NF-κB pathways in determining targets for new glioma 
therapy.  We then expanded on this molecular knowledge by evaluating the clinical 
correlations with genes in the expression and receptor-mediated induction of TWEAK to 
show that expression of TWEAK, FN14, and NIK are increased in gliomas with poorer 
prognosis. The questions addressed in this dissertation are: 
 How does upstream and extracellular activation of the noncanonical NF-κB 
pathway affect glioma invasion and tumorigenesis? 
 What is the clinical context for expression of TWEAK-Axis genes? 
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This dissertation contributes new findings for glioma:  
 The noncanonical NF-κB pathway is differentially expressed in gliomas and 
drives invasion and tumorigenesis independently of the canonical NF-κB 
pathway.  
 Low-dose TWEAK is capable of exclusively activating the noncanonical NF-κB 
pathway and promoting invasion in multiple glioma lines.  
 Expression of genes encoding TWEAK, its receptor FN14, and NIK correlate 
positively with poor prognostic factors and the Mesenchymal glioma subtype. 
Overall, our findings suggest that noncanonical NF-κB potentially contributes more to 
the invasive phenotype of glioma than canonical NF-κB signaling, especially in the 
Mesenchymal subtype. Canonical NF-κB proteins are expressed in glioma and can be 
activated by TNFα through induction of IκBα degradation, RelA phosphorylation, RelA 
translocation to the nucleus, and delayed induction of noncanonical NF-κB signaling, as 
we also have shown in this work. Thus, the canonical NF-κB pathway is intact in all 
cells we studied and is more-often-studied in glioma because it is consistently present 
and better-understood rather than biologically relevant in glioma. A significant discovery 
in our work was that TWEAK was able to induce invasion in the glioma cells with 
complete absence of canonical NF-κB activation. Noncanonical NF-κB signaling alone 
is sufficient to increase invasion, highlighting a substantial gap in our understanding of 
both pathways in gliomagenesis and progression. We therefore propose that it is the 
acquisition of the noncanonical NF-κB pathway, rather than increased activity of an 
ubiquitous canonical NF-κB pathway, that is more relevant to glioma pathogenesis. 
Whereas other studies have shown high-dose TWEAK increases glioma migration in a 
canonical-NF-κB-dependent manner [105, 116], our work demonstrated a noncanonical-
NF-κB-specific response to low-dose TWEAK in invasion. This agrees with previous 
reports of differential canonical or noncanonical NF-κB responses from different 
concentrations of soluble TWEAK [94], which has been primarily advancing in the field 
of mesenchymal tissue development such as myoblast maturation [153]. To that end, 
increased expression of TWEAK Axis genes MAP3K14, TRAF3, TNFSF12, and 
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TNFRSF12A and noncanonical NF-κB in glioma may indicate acquisition of an intact 
pathway of mesenchymal differentiation and invasion in glioma. There is value in 
validating molecular findings in mesenchymal developmental biology in glioma to 
determine which natural pathways are intact. Accounting for which genes and proteins 
are shared between mesenchymal development in mesenchymal cells and mesenchymal 
phenotype development in glioma would allow for a more complete understanding of 
signaling in glioma and potentially identify additional targets for therapy. Therefore, the 
studies of mesenchymal development and Mesenchymal subtype glioma could 
complement each other in the development of mesenchymal-specific therapies.   
We utilized BT lines from patient samples from Mayo Clinic as well as ATCC-
derived lines widely used in glioma research. We demonstrated that TWEAK 
significantly increased invasion in all cell lines, even the non-invasive BT114 line with 
minimal basal protein levels of RelB. We showed for the first time in reported literature 
that TWEAK is capable of inducing NIK mRNA expression. The current understanding 
of NIK regulation emphasizes post-transcriptional regulation as the primary mechanism 
to control NIK activity [68]. Interestingly, increased mRNA expression was mild in the 
2-3 fold range which, combined with only rare incidences of NIK expression greater 
than 2 fold in NCI array data, suggests that NIK upregulation is likely not a major 
contributor to glioma pathogenesis. This is further supported by our observation that 
ectopic wild-type NIK increased invasion but not significantly. Rather, NIK may be an 
instrumental component of transmitting TWEAK/FN14 activation rather than an 
independent driver of the noncanonical NF-κB invasive phenotype. TRAF3 expression 
has little significant relevance to prognostic factors, which further suggests that NIK 
overexpression or decreased negative regulation are not major mechanisms of glioma 
pathogenesis. Significantly improved survival in the highest and lowest quartiles of 
MAP3K14 expression supports NIK expression is nonetheless important in glioma, 
presumably by propagating TWEAK and other extracellular activators of NF-κB. Not 
investigated in this study were effects of TWEAK on the expression of other 
noncanonical NF-κB genes, which would provide insight into a role of TWEAK in the 
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induction of the mesenchymal phenotype in glioma cells. Although the Mesenchymal 
subtype can be inferred from the elongated mesenchymal-like invading phenotype in 
BT116 and U87 cells as well as the MMP-dependent invasion response, we cannot 
definitively categorize the BT or ATCC lines without sophisticated analysis of 
comprehensive gene expression data. We report that TWEAK seems to specifically 
induce MMP9 mRNA expression, but not the other gelatinase MMP2 or inducible 
membrane-type collagenase MMP14. A complete panel of MMP induction by TWEAK 
may show additional MMP induction or activity worth evaluating in glioma invasion and 
clinical outcome. Taken together with pan-inhibition, there appears to be a functional 
rather than reporting role for MMP9 in glioma cell invasion in type 1 collagen, which is 
unusual given that MMP9 is usually considered a gelatinase. This does not rule out the 
possibility of MMP9 activating cell-surface proteins to induce invasion. This could be 
more directly measured by MMP9 activity following TWEAK treatment with an 
enzymatic assay. The purpose of this study was to evaluate activation and regulation of 
MMP9 expression of the noncanonical NF-κB pathway by NIK stabilization and p100 
processing using TWEAK as a noncanonical NF-κB-specific ligand. It would therefore 
be useful to perform a microarray or sequencing experiment on our glioma cell lines to 
stratify them into glioblastoma subtypes and ratify our molecular biology findings and 
gene expression data from the NCI dataset with the cell lines used.  
Nuclear translocation of RelA and RelB following treatment TWEAK versus 
TNFα indicate that activation of either pathway in glioma is specific rather than 
redundant. We posit that both pathways must be addressed in context when evaluating 
potential NF-κB-targeted therapies. A considerable challenge in the development of 
therapeutics towards NF-κB constituents in glioma or other cancers is the poor 
drugability of transcription factors. A molecular basis for selective RelA or RelB binding 
to a specific promotor is an active but unresolved area of research [51], which makes 
specific inhibition of DNA-protein interaction for RelA versus RelB currently 
impossible. Pharmacologic inhibition of upstream kinases and extracellular 
ligand/receptor interactions provide a more promising approach. A recent study by 
 65 
 
Zanotto-Filho et al. has shown that in vitro anti-NF-κB therapy selectively decreased 
proliferation in a panel of glioma lines versus normal astrocyte lines [154].  Anti-NF-κB 
therapy also increased sensitization to cisplatin and doxorubicin [154]. The specific anti-
NF-κB compounds were anti-inflammatories, proteasome inhibitors, and an IKKβ 
inhibitor. Considerable attention is dedicated to IKKβ inhibitors as the catalytic subunit 
of the trimeric IKK complex that phosphorylates IκBα for degradation, but selectivity 
versus IKKα components is poor [155]. Ubiquitously-expressed canonical NF-κB has a 
wide variety of cellular functions in different tissues throughout the body, making 
systemic side-effects a concern. Because of poor IKKα/IKKβ selectivity, NIK is the 
most promising choice for kinase inhibition of the noncanonical NF-κB pathway. NIK 
inhibitor design in silico is an active area of research [156, 157], and pre-clinical studies 
in vitro have shown inhibition of cell viability and p100 processing in multiple myeloma 
[158].  Given these results in multiple myeloma and our data showing that NIK can drive 
glioma tumor development, evaluation of NIK inhibitors in glioma is of considerable 
interest. Our work offers NIK and TWEAK as promising therapeutic targets that 
specifically activate the noncanonical NF-κB pathway and increase invasion in glioma, 
which is a particularly deadly and concerning characteristic of high-grade gliomas that 
makes surgical resection difficult, high-dose chemotherapy and radiation necessary, and 
recurrence inevitable. A new hypothesis generated from our work would be how 
inhibition of NIK, TWEAK, or FN14 affects noncanonical NF-κB activation and glioma 
invasion. Anti-TNFα antibodies (adalimumab) and decoy receptors (etanercept) are 
already in clinical use as anti-inflammatory agents [159, 160], indicating proof-of-
principle for the development of anti-TWEAK antibodies or decoy receptors. Decoy 
FN14-Fc receptors of TWEAK have been shown to inhibit TWEAK-stimulated glioma 
migration [105]. Recent work in developing blood-brain barrier-penetrant TNFα decoy 
receptors for stroke highlights the possibility of developing brain-penetrating anti-
TWEAK decoy receptors [161]. An FN14-ligand fusion protein has been shown to 
induce HCC apoptosis and reduce tumor volume in mice models [115]. Ostensibly, these 
receptors would inhibit TWEAK and its extracellular activation of noncanonical NF-κB 
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and subsequent invasion. A small-molecule inhibitor of TWEAK/FN14 would provide 
an additional tool to assess the drugability of the TWEAK axis in the treatment of 
glioma. Very recently, an abstract at the 2014 Annual Scientific Meeting of the Society 
for Neuro-Oncology described a cell-based screening for inhibitors of TWEAK-induced 
migration in glioma and identified aurintricarboxylic acid (ATA) as an inhibitor of 
TWEAK/FN14 signaling. We summarize our model of TWEAK-activated noncanonical 
NF-κB signaling in glioma and its potential therapeutic strategies in Figure 15. 
 
 
Figure 15 Proposed model for TWEAK/FN14 activation of noncanonical NF-κB in glioma invasion. 
 67 
 
Our study provides initial rationale for targeting the TWEAK Axis and subsequent 
activation of noncanonical NF-κB clinically in the treatment of high-grade glioma, but 
evaluation of TWEAK inhibition in vitro and in vivo is required as a pre-clinical study. 
Although our work clearly demonstrates a pro-invasive effect of TWEAK and 
the noncanonical NF-κB pathway in glioma invasion and clinical outcome, there are 
limitations to address. First, our loss-of-function studies for RelA, RelB, NFKB2, and 
NIK utilized a traditional shRNA approach. Individual shRNA constructs were selected 
from a panel of confirmed knockdowns for robustness and to reduce the likelihood of 
off-target effects. However, knockdown efficiency is a limitation in the robustness and 
therefore power of shRNA to determine significant effects of knockdown of the protein 
of interest. Incomplete RNA interference is particularly challenging in proteins with 
constitutive activity such as NIK, where incomplete interference may be insufficient to 
demonstrate a significant effect. Clustered Regularly Interspaced Short Palindromic 
Repeat (CRISPR) interference is an advanced technique that inhibits transcription of the 
gene of interest with improved efficiency and specificity versus RNA interference [162].  
Utilization of CRISPR as a more powerful interference technique should further validate 
the significance of reduced NF-κB expression in glioma invasion.  
Second, we observed significant increases in invasion despite less p100 
processing in the NIK S867A mutant versus the wild-type NIK construct. These results 
suggest that the mutant exerts its effects beyond inherent constitutive activity of 
stabilized NIK, a concern not addressed in this work. Addressing the relevance of the 
TRAF3-binding domain, kinase domain, and other regulatory domains is the subject of a 
mutational analysis of NIK currently being investigated by another student in our lab. 
From this analysis we hope to further a fundamental understanding of NIK regulation 
and its function in glioma.  
Third, our differential gene analysis was descriptive and requires caution in the 
interpretation. Because the cohort was large, the significance of the Spearman 
correlation ρ-values indicates they are dependable, but significance does not indicate 
whether these weak and moderate correlations are descriptive biologically. Biological 
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significance of each of these correlations would have to be investigated directly to 
account for complex and indirect interactions between genes that may have a 
functionally significant biological effect. Analysis of Covariance (ANCOVA) is a 
sophisticated technique to merge correlation between multiple gene expression values 
and linear regression of their contributions to a biological effect [163, 164]. ANCOVA 
utilizes Gene Ontology from known biological interactions reported in literature to score 
and group correlations between genes statistically as well as functionally. We have set 
up a framework for additional and more-sophisticated analysis of our combined NCI 
dataset with experienced bioinformaticists.  
Fourth, gene expression analysis using DNA microarray has well-known 
limitations. Fortunately, batch effects and data quality were verified by TCGA and 
REMBRANDT requirements as well as externally validated [13, 23, 146]. Probe design 
is a priori and does not account for specific abnormal or noncoding RNA unless 
specifically designated. The NCI databases utilized human genome chips to assay the 
maximum number of wild-type human genes and were not specifically tailored to assess 
molecular events clinically relevant to such as mutations, alternative splicing, or 
promoter methylation status known to high-grade gliomas. RNAseq data is available in 
the TCGA, but because many of the RNAseq datasets contain the same tumor samples as 
the microarray sets we did not utilize RNAseq data due to the increased computing 
power, additional software, and complexity in interpreting quality and meaning of 
results. RNAseq data has promising applications in identifying clinically-relevant gene 
expression, mutations, and single nucleotide polymorphisms throughout the glioma 
genome rather than determined a priori like gene arrays. Determining agreement 
between microarray technology and next-generation sequencing and evaluating the 
comparative utility of the two is a worthwhile endeavor, but is well beyond the scope of 
this project and would best be conducted in collaboration with an experienced 
bioinformaticist. 
Finally, all data available from the TCGA and REMBRANDT were from 
primary and not recurrent tumors. Our analysis would be informative in evaluating 
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noncanonical NF-κB and TWEAK Axis expression in recurrent tumors. Although 
samples from recurrent tumors for some of the TCGA patients are indicated in the 
clinical manifests, expression data from these samples is not accessible. It has been 
proposed by Phillips et al. that recurrent tumors are mesenchymal regardless of the 
subtype of the initial tumor [11]. If this is true, the relevance of TWEAK and 
noncanonical NF-κB would have to be evaluated in context of both the initial tumor 
subtype and whether TWEAK correlates with prognosis of recurrent tumors that are 
ultimately fatal. Therapeutic regimes and recurrence status are inconsistently annotated 
in the TCGA and REMBRANDT databases. Therefore, additional focused clinical 
studies are required to correlate TWEAK Axis expression with clinical outcome in the 
context of clinical strategies at initial diagnosis and recurrence. 
In this work we combined a molecular & cellular biology approach as well as 
descriptive statistics to gene expression data for biological functional significance of 
TWEAK and NIK as well as clinical statistical significance of TWEAK, NIK, FN14, 
and TRAF3 gene expression. We therefore propose TWEAK signaling contributes to 
advanced glioma pathogenesis. Collectively, our work addresses a gap in knowledge of 
noncanonical NF-κB signaling in glioma invasion and tumorigenesis. We show that the 
TWEAK-noncanonical NF-κB pathway is clinically relevant and mandates additional 
study to advance fundamental and translational opportunities to improve outcome in a 
large cohort of patients with a devastating disease.   
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APPENDIX A 
SUPPLEMENTAL FIGURES 
 
Figure A1 Efficiency of RelA knockdown among multiple shRNA constructs and quantification of 
RelB overexpression. (A) Quantification of invasion density at 48 h for U87 RelA knockdown cell lines 
1-4. Data represent average numbers of invading cells per 1-mm2 field (n = 3 wells) ± SEM. **p < 0.01 
***p < 0.001 relative to shCon using One-way ANOVA with Tukey’s HSD post-test. (B) Western blot of 
whole-cell lysates from U87 shRelA glioma lines using the indicated antibodies. Numbers indicate semi-
quantitative measurements of RelA protein levels relative to actin protein levels and normalized to shCon. 
(C) Semi-quantitative measurement RelB protein levels relative to actin protein levels for western blot of 
whole-cell lysates from U87 shCon and shRelA cells transduced with RFP cDNA (+Vector) or RelB 
cDNA (+RelB) from Figure 2D. Data are normalized to shCon. †Data contributed by DW Lee. 
† 
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Figure A2 TWEAK specifically induces noncanonical NF-κB activation in glioma cells via NIK 
protein accumulation. (A) Western blot analysis of proteins from cytoplasmic and nuclear fractions of 
BT116 cells stimulated with 10 ng/ml TWEAK at indicated times using the indicated antibodies. (B)  
Western blot analysis of BT116 glioma cell lysates at indicated time post-treatment with 10 ng/ml 
TWEAK and 5µM proteasome inhibitor MG132 using the indicated antibodies. White arrowhead indicates 
NIK band. Black arrowhead indicates non-specific band. †Data contributed by DW Lee. 
† 
† 
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Figure A3 TWEAK-enhanced invasion is attenuated by broad-spectrum MMP and MMP9-selective 
inhibition. (A) Quantification of invasion density at 48 h for U87 cells with or without 10 ng/ml TWEAK 
in the collagen matrix. Cells were treated during the 48 h invasion assay with broad-spectrum MMP 
inhibitor GM6001 at indicated concentrations. Data represent average numbers of invading cells per 1-
mm2 field (n = 3 wells) ± SEM. *p < 0.05 ***p < 0.001 between indicated groups using unpaired 
Student’s t-test.  (B) Quantification of invasion density at 48 h for U87 cells with or without 10 ng/ml 
TWEAK in the collagen matrix. Cells were treated during the 48 h invasion assay with MMP9-specific 
Inhibitor I at indicated concentrations. Data represent average numbers of invading cells per 1-mm2 field 
(n = 3 wells) ± SEM. *p < 0.05 **p < 0.01 ***p < 0.001 between indicated groups using unpaired 
Student’s t-test. 
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Figure A4 NIK overexpression specifically induces p100 processing in glioma cells. (A) Western blot 
analysis of BT114 glioma cells transduced with lentivirus containing NIK cDNA or luciferase cDNA 
(Con) using the indicated antibodies. White arrowhead indicates NIK band. Black arrowhead indicates 
non-specific band. †Data contributed by DW Lee. 
  
† 
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Figure A5 Expression of subtype marker genes stratified by glioblastoma subtype. (A) EGFR, (B) 
CHI3L1, (C) MBP, and (D) OLIG2 expression values from microarray data. Data represent median log2 
expression with boxes indicating upper and lower quartile and whiskers indicating range. *p < 0.05, **p < 
0.01, ***p < 0.001, n.s.d. no significant difference using Kruskal-Wallis test with Dunn’s post-test. (E) 
Summary table of subtype marker gene expression within glioblastoma subtype. Data represent average 
log2 expression ± SEM. 
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APPENDIX B 
SUPPLEMENTAL TABLES 
 
Table B1 GSEA genes correlated with Verhaak et al. subtypes 
 
Classical Mesenchymal Neural Proneural 
ABCD2 ACPP ACSL4 ABAT 
ACSBG1 ACSL1 ACYP2 ACTR1A 
ACSL3 ADAM12 ADD3 ALCAM 
ACSS3 AIM1 AGTPBP1 AMOTL2 
ADAM19 ALDH3B1 AGXT2L1 ARHGAP33 
AKT2 ALOX5 AKR7A3 ARHGEF9 
ANXA5 AMPD3 ANKRD46 ASCL1 
APBA3 ANXA1 ANKS1B ATAD5 
ARAP2 ANXA2 ANXA3 ATAT1 
ARAP3 ANXA4 ANXA7 ATP1A3 
ARNTL ARHGAP29 ARRB1 BAI3 
B3GALT1 ARPC1B ATP5F1 BCAN 
BLM ARSJ ATP5L BCL7A 
BTBD2 ASL ATRNL1 BCOR 
C19orf22 BATF BASP1 BEX1 
C19orf66 BDKRB2 BCAS1 C1orf106 
CALM1 BLVRB BEST1 C1orf61 
CAMK2B BNC2 C17orf108 C1QL1 
CC2D1A C1orf38 CA4 CA10 
CD151 C1orf54 CALM2 CAMSAP2 
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Classical Mesenchymal Neural Proneural 
CD3EAP C5AR1 CAMK2G CASK 
CD97 CASP1 CASQ1 CBX1 
CDH2 CASP4 CCDC121 CDC25A 
CDH4 CASP5 CCK CDC7 
CDH6 CASP8 CDC42 CDK5R1 
CDK6 CAST CDR1 CDKN1B 
CLIP2 CCDC109B CHN1 CELF3 
CREB5 CCR5 CLCA4 CHD7 
DAG1 CD14 COX5B CKB 
DENND2A CD2AP CPNE6 CLASP2 
DLC1 CD4 CRBN CLGN 
DMWD CDCP1 CRYL1 CNTN1 
DOCK6 CEBPB CRYM CRB1 
EGFR CHI3L1 CRYZL1 CRMP1 
ELOVL2 CLCF1 CUTC CSNK1E 
EPHB4 CLEC2B CYTH1 CSPG5 
ERCC2 CLIC1 DHRS9 CXXC4 
EXTL3 CNN2 DYNC1I1 DBN1 
EYA2 COL1A1 EDIL3 DCAF7 
FBXO17 COL1A2 ENPP2 DCX 
FGFR3 COL5A1 ENPP4 DGKI 
FZD3 COL8A2 EPB41L3 DLL3 
FZD7 COPZ2 EVI2A DNM3 
GALNT4 CSTA FAM49B DPF1 
GAS1 CTSB FBXO3 DPP6 
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Classical Mesenchymal Neural Proneural 
GJA1 CTSC FEZF2 DPYSL4 
GLG1 CTSZ FHIT DUSP26 
GLI2 CYBRD1 FUT9 E2F3 
GNAS CYTH4 FXYD1 EPB41 
GNG7 CYTIP GABARAPL2 EPHB1 
GPR56 DAB2 GABRB2 ERBB3 
GRIK1 DCBLD2 GNAI1 FAM110B 
GRIK5 DOK3 GPR22 FAM125B 
GSTK1 DRAM1 GRM1 FBXO21 
HMG20B DSC2 GRM3 FERMT1 
HS3ST3B1 DSE GUK1 FGF9 
HSPBP1 EFEMP2 HPCA FHOD3 
ILK EHD2 HPCAL4 FLRT1 
IRF3 ELF4 HPRT1 FXYD6 
IRS2 EMP3 IMPA1 GABRA3 
ITGA7 ENG KCNJ3 GADD45G 
ITGB8 FCGR2A KCNK1 GNG4 
JAG1 FCGR2B KIAA1598 GPM6A 
JUND FES LYRM1 GPR17 
KCNF1 FHL2 MAGEH1 GRIA2 
KEAP1 FHOD1 MAT2B GRID2 
KIAA0355 FMNL1 MBP GSK3B 
KLHDC8A FNDC3B MDH1 GSTA4 
KLHL25 FOLR2 MGC72080 HDAC2 
KLHL4 FPR3 MGST3 HMGB3 
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Classical Mesenchymal Neural Proneural 
LAMB2 FURIN MMD HN1 
LFNG FXYD5 MORF4L2 HOXD3 
LHFP GCNT1 MRPL49 HRASLS 
LMO2 GLT25D1 MSRB2 ICK 
LRFN3 GNA15 MYBPC1 IL1RAPL1 
LRP10 GRN NANOS1 KAT7 
LRP5 HEXA NDRG2 KDM1A 
LRRC16A HEXB NDUFS3 KIF21B 
MAB21L1 HFE NSL1 KLRC3 
MCC HK3 NTSR2 KLRC4 
MEGF8 ICAM3 ORC4 KLRK1 
MEIS1 IFI30 PARP8 LOC81691 
MEOX2 IGFBP6 PDE6D LPAR4 
MGC2752 IL15RA PEX11B LPHN3 
MLC1 IL1R1 PEX19 LRP6 
MYO5C IL4R PGBD5 LRRTM4 
NDP IQGAP1 PLCL1 MAP2 
NES ITGA4 POPDC3 MAPT 
NOS2 ITGA5 PPA1 MARCKS 
NPAS3 ITGAM PPFIA2 MARCKSL1 
NPEPL1 ITGB2 PPP1R1A MAST1 
NR2E1 KYNU PPP2R5A MATR3 
NR2F6 LAIR1 PRPSAP2 MCM10 
OSBPL3 LAMB1 REPS2 MLLT11 
PCSK5 LAPTM5 RERGL MMP15 
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Classical Mesenchymal Neural Proneural 
PDGFA LCP1 RND1 MMP16 
PEPD LCP2 ROGDI MPPED2 
PIPOX LGALS1 S1PR1 MTSS1 
PLA2G5 LGALS3 SAR1A MYB 
PLIN3 LHFPL2 SCHIP1 MYO10 
PMP22 LILRB2 SEPP1 MYT1 
POFUT1 LILRB3 SEPW1 NCALD 
POMT2 LOX SERPINI1 NCAM1 
PRKD2 LRRFIP1 SGK3 NKAIN1 
PRPF31 LTBP1 SH3GL2 NKX2-2 
PTPN14 LTBP2 SH3GL3 NLGN3 
PTPRA LY75 SIRT5 NOL4 
QTRT1 LY96 SLC16A7 NR0B1 
RASGRP1 MAFB SLC30A10 NRXN1 
RBCK1 MAN1A1 SLC31A2 NRXN2 
RBM42 MAN2A1 SLCO1A2 OLIG2 
RFX2 MAN2B1 SNCG P2RX7 
RFXANK MAPK13 SNX11 PAFAH1B3 
RGS12 MFSD1 SPAST PAK3 
RGS6 MGAT1 TCEAL1 PAK7 
RIN1 MGST2 TCEAL2 PCDH11X 
SARS2 MRC2 THTPA PCDH11Y 
SCAMP4 MS4A4A TMEM144 PDE10A 
SEMA6A MSR1 TPM3 PELI1 
SEMA6D MVP TSNAX PFN2 
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Classical Mesenchymal Neural Proneural 
SEPT11 MYH9 TTC1 PHF16 
SHOX2 MYO1F TTPA PHLPP1 
SIPA1L1 MYOF UGT8 PLCB4 
SLC12A4 NCF2 UROS PODXL2 
SLC2A10 NCF4 USP33 PPM1D 
SLC4A4 NOD2 VIP PPM1E 
SLC6A11 NPC2 VSX1 PURG 
SLC6A9 NR4A3 YPEL5 RAB33A 
SMO NRP1 ZNF323 RAD21 
SNTA1 P4HA2  RALGPS1 
SOCS2 PDPN  RALGPS2 
SOX9 PGCP  RAP2A 
SPRY2 PHF11  RBPJ 
SSH3 PIGP  REEP1 
TBX2 PLA2G15  RNFT2 
TEAD3 PLAU  RUFY3 
TGFB3 PLAUR  SATB1 
TGIF2 PLBD1  SCG3 
TLE2 PLK3  SCN3A 
TMED1 PLS3  SEC61A2 
TMEM147 POLD4  SEZ6L 
TMEM161A PROCR  SLC1A1 
TRIB2 PTGER4  SLCO5A1 
TRIP6 PTPN22  SORCS3 
VAV3 PTPN6  SOX10 
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Classical Mesenchymal Neural Proneural 
VPS16 PTPRC  SOX11 
WSCD1 PTRF  SOX2 
ZFHX4 PYGL  SOX4 
ZFP112 RAB11FIP1  SPTBN2 
ZNF134 RAB27A  SRGAP3 
ZNF20 RAB32  STMN1 
ZNF211 RABGAP1L  STMN4 
ZNF227 RAC2  TAF5 
ZNF235 RBKS  TMCC1 
ZNF264 RBM47  TMEFF1 
ZNF304 RBMS1  TMEM35 
ZNF419 RELB  TMSB15A 
ZNF446 RHOG  TOP2B 
ZNF45 RRAS  TOPBP1 
ZNF606 RUNX2  TOX3 
ZNF671 S100A11  TSPAN3 
ZNF8 S100A13  TTC3 
 S100A4  TTYH1 
 SAT1  VAX2 
 SCPEP1  VEZF1 
 SEC24D  WASF1 
 SERPINA1  YPEL1 
 SERPINE1  ZC4H2 
 SFT2D2  ZEB2 
 SH2B3  ZNF184 
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Classical Mesenchymal Neural Proneural 
 SHC1  ZNF248 
 SIGLEC7  ZNF286A 
 SIGLEC9  ZNF510 
 SLAMF8  ZNF643 
 SLC10A3  ZNF711 
 SLC11A1  ZNF804A 
 SLC16A3  ZNF821 
 
SP100   
 
SQRDL   
 
SRPX2   
 
ST14   
 
STAB1   
 
STAT6   
 
STXBP2   
 
SWAP70   
 
SYNGR2   
 
SYPL1   
 
TCIRG1   
 
TES   
 
TGFBI   
 
TGFBR2   
 
TGOLN2   
 
THBD   
 
THBS1   
 
TIMP1   
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Classical Mesenchymal Neural Proneural 
 
TLR2   
 
TLR4   
 
TMBIM1   
 
TNFAIP3   
 
TNFAIP8   
 
TNFRSF11A   
 
TNFRSF1A   
 
TNFRSF1B   
 
TRADD   
 
TRIM22   
 
TRIM38   
 
TRPM2   
 
TYMP   
 
UAP1   
 
UCP2   
 
VAMP5   
 
VDR   
 
WIPF1   
 
WWTR1   
 
YAP1   
 
ZNF217   
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Table B2 NCI Dataset Summaries 
 
Source Sample 
Types 
Dataset Clinical 
Data/ 
Total 
Samples 
Platform 
REMBRANDT 
(ArrayExpress) 
LGG 
GBM 
E-MTAB-3073^ 287/522 
Affymetrix 
HG_U133_Plus_2 
TCGA GBM UNC__AgilentGF4502A_07_1# 102/122 Agilent GF4502A_07 
TCGA GBM UNC__AgilentGF4502A_07_2# 467/483 Agilent GF4502A_07 
TCGA LGG UNC__AgilentGF4502A_07_3# 27/27 Agilent GF4502A_07 
Total 
LGG 
GBM 
 883/1153  
GBM Glioblastoma, LGG Lower Grade Glioma; ^RMA/Quantile-normalized, #LOWESS-normalized 
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Table B3 Entrez Gene IDs for probesets 
 
Gene Name Entrez Gene ID Protein Category 
MAP3K14 9020 NIK 
TWEAK Axis, NF-κB 
(Noncanonical) 
TRAF3 7187 TRAF3 TWEAK Axis, NF-κB 
TNFSF12 8742 TWEAK TWEAK Axis, NF-κB 
TNFRSF12A 51330 FN14 (TWEAKR) TWEAK Axis, NF-κB 
    
EGFR 1956 EGFR Classical 
MBP 4155 MBP Neural 
COL1A1 1277 Collagen Type 1 α1 Invasion, Mesenchymal 
MMP9 4318 MMP9 Invasion 
MET 4233 c-MET (HGFR) Mesenchymal 
CHI3L1 1116 CHI3L1 Mesenchymal 
SOX2 6657 SOX2 Proneural 
OLIG2 10215 OLIG2 Proneural 
    
REL 5966 c-Rel NF-κB 
RELA 5970 RelA NF-κB (Canonical) 
RELB 5971 RelB NF-κB (Noncanonical) 
CHUK 1147 IKKα 
NF-κB (Canonical & 
Noncanonical) 
IKBKB 3551 IKKβ NF-κB (Canonical) 
IKBKG 8517 IKKγ (NEMO) NF-κB (Canonical) 
NFKB1 4790 p105/p50 NF-κB (Canonical) 
NFKB2 4791 p100/p52 NF-κB (Noncanonical) 
NFKBIA 4792 IκBα NF-κB (Canonical) 
TNF 7124 TNFα 
NF-κB (Canonical & 
Noncanonical) 
TNFRSF1A 7132 TNFR1 
NF-κB (Canonical & 
Noncanonical) 
 
